https://www.fondazionebonadonna.eu/news/ 2026-09-02T10:34:13+00:00 https://www.fondazionebonadonna.eu/tumori-solidi-con-un-alto-numero-di-mutazioni-buoni-risultati-con-atezolizumab/ 2021-04-21T07:55:03+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/04/Depositphotos_171921106_ds_FGB.jpg https://www.fondazionebonadonna.eu/inibire-le-fusioni-ret-e-una-strategia-efficace-in-piu-tumori-del-previsto/ 2021-04-21T07:55:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/04/Depositphotos_184231854_ds_FGB.jpg https://www.fondazionebonadonna.eu/un-proteina-bifronte-per-il-melanoma-uveale-metastatico/ 2021-04-21T07:55:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/04/Depositphotos_190939978_ds_FGB.jpg https://www.fondazionebonadonna.eu/combinare-citochine-e-inibitori-dei-checkpoint-un-approccio-sicuro-e-promettente/ 2021-04-21T07:55:59+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/04/Depositphotos_55285531_ds_FGB.jpg https://www.fondazionebonadonna.eu/un-test-sul-dna-circolante-per-diagnosticare-oltre-50-tumori/ 2021-05-03T06:35:05+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/04/News_3May21.jpg https://www.fondazionebonadonna.eu/tumore-al-seno-il-ruolo-dei-fibroblasti-associati-al-cancro/ 2021-05-10T08:00:59+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/05/6_10May21.jpg https://www.fondazionebonadonna.eu/un-approccio-multi-omico-integrato-per-la-terapia-dei-tumori/ 2021-05-24T08:00:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/05/Depositphotos_143506255_2500.jpg https://www.fondazionebonadonna.eu/lalto-carico-mutazionale-non-predice-la-risposta-allimmunoterapia-in-tutti-i-tumori/ 2021-05-31T08:00:59+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/05/Depositphotos_311079512_2500.jpg https://www.fondazionebonadonna.eu/un-farmaco-immuno-coniugato-contro-il-tumore-al-seno-triplo-negativo-metastatico/ 2021-05-17T13:38:46+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/05/Depositphotos_47049101_2500.jpg https://www.fondazionebonadonna.eu/pagina-mastro-news/ 2021-06-07T08:00:52+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_250907726_ds_2500.jpg https://www.fondazionebonadonna.eu/linfoma-individuato-un-tallone-dachille-nelle-vie-a-valle-della-sirtuina-3/ 2021-06-14T08:00:00+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_8021841_ds_2500.jpg https://www.fondazionebonadonna.eu/tumore-uroteliale-avanzato-una-combinazione-di-durvalumab-e-farmaci-targeted-e-poco-efficace/ 2021-06-28T08:00:25+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_273021368_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/tumori-a-origine-sconosciuta-una-speranza-dagli-inibitori-mek/ 2021-07-05T08:00:16+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_287373068_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/scarsi-risultati-con-venetoclax-nel-tumore-al-seno-avanzato-o-metastatico/ 2021-07-12T08:00:31+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/en/lymphoma-an-achilles-heel-identified-downstream-sirtuin-3/ 2021-06-29T16:32:56+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_8021841_ds_2500.jpg https://www.fondazionebonadonna.eu/en/osteosarcomas-a-new-molecular-target-identified-with-surfeceome-profiling/ 2021-06-29T16:33:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_250907726_ds_2500.jpg https://www.fondazionebonadonna.eu/en/high-tumor-mutation-burden-predicts-immunotherapy-response-in-some-but-not-all-cancers/ 2021-06-29T16:33:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/05/Depositphotos_311079512_2500.jpg https://www.fondazionebonadonna.eu/en/an-integrated-multi-omic-approach-for-a-personalized-cancer-treatment/ 2021-06-29T16:33:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/05/Depositphotos_143506255_2500.jpg https://www.fondazionebonadonna.eu/en/an-antibody-drug-conjugate-against-metastatic-triple-negative-breast-cancer/ 2021-06-29T16:33:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/05/Depositphotos_47049101_2500.jpg https://www.fondazionebonadonna.eu/en/breast-cancer-the-role-of-cancer-associated-fibroblasts/ 2021-06-29T16:33:57+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/05/6_10May21.jpg https://www.fondazionebonadonna.eu/en/advanced-urothelial-cancer-questionable-efficacy-of-durvalumab-in-combination-with-different-targeted-drugs/ 2021-06-29T16:34:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_273021368_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/tumori-a-origine-sconosciuta-dallitalia-un-modello-di-studio-per-risolvere-il-loro-enigma/ 2021-07-13T09:46:42+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_7854468_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/en/tumors-of-unknown-origin-an-italian-study-model-to-solve-their-enigma/ 2021-07-13T09:49:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_7854468_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/en/cancers-of-unknown-origin-hope-from-mek-inhibitors/ 2021-07-13T09:50:59+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_287373068_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/chiuso-il-primo-bando-per-borse-di-studio-cofinanziate-da-fondazione-gianni-bonadonna-e-fondazione-airc/ 2021-07-26T09:32:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/fgb07.jpg https://www.fondazionebonadonna.eu/en/stop-to-applications-for-the-first-gianni-bonadonna-foundation-airc-foundation-fellowship/ 2021-07-26T10:22:10+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/fgb07.jpg https://www.fondazionebonadonna.eu/agnosfere-e-analisi-molecolare-per-trovare-terapie-per-i-tumori-a-origine-sconosciuta/ 2021-07-27T15:36:42+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_60205583_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/agnosfere-e-analisi-molecolare-per-trovare-terapie-per-i-tumori-a-origine-sconosciuta/ 2021-07-27T15:38:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_60205583_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/en/agnospheres-and-molecular-analysis-to-find-therapies-for-tumors-of-unknown-origin/ 2021-07-27T15:42:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_60205583_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/unimmunoterapia-efficace-nel-tumore-al-seno-triplo-negativo/ 2021-08-09T08:00:28+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/FGB_Depositphotos_112249332_xl-2015.jpg https://www.fondazionebonadonna.eu/un-biologo-computazionale-torna-da-cambridge-per-fondazione-gianni-bonadonna/ 2021-08-30T08:00:58+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/08/FGB_Depositphotos_155745262_xl-2015.jpg https://www.fondazionebonadonna.eu/tumore-alla-prostata-allo-studio-un-ruolo-per-i-p38-inibitori/ 2021-09-06T08:00:02+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/08/FGB_Depositphotos_7854675_xl-2015.jpg https://www.fondazionebonadonna.eu/en/an-effective-immunotherapy-for-triple-negative-breast-cancer/ 2021-08-09T08:07:46+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/FGB_Depositphotos_112249332_xl-2015.jpg https://www.fondazionebonadonna.eu/en/poor-results-with-venetoclax-in-advanced-or-metastatic-breast-cancer/ 2021-08-26T11:11:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/nel-tumore-al-seno-her-2-negativo-lespressione-dei-geni-mhc-ii-da-informazioni-sulla-probabilita-di-ottenere-una-buona-risposta-con-limmunoterapia/ 2021-08-26T13:04:59+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/FGB_Depositphotos_239038586_xl-2015.jpg https://www.fondazionebonadonna.eu/en/anti-pd-1-therapy-evaluating-tumor-specific-mhc-ii-expression-to-predict-clinical-benefits/ 2021-08-26T13:16:00+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/FGB_Depositphotos_239038586_xl-2015.jpg https://www.fondazionebonadonna.eu/en/a-bioinformatician-comes-back-from-cambridge-for-the-gianni-bonadonna-foundation/ 2021-08-30T08:20:39+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/08/FGB_Depositphotos_155745262_xl-2015.jpg https://www.fondazionebonadonna.eu/en/prostate-cancer-a-possible-role-for-p38-inhibitors/ 2021-09-06T08:03:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/08/FGB_Depositphotos_7854675_xl-2015.jpg https://www.fondazionebonadonna.eu/la-ricerca-di-fondazione-michelangelo-a-esmo-2021/ 2021-09-13T12:39:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/Depositphotos_7451136_xl-2015.jpg https://www.fondazionebonadonna.eu/en/research-from-michelangelo-foundation-at-esmo-2021/ 2021-09-14T12:41:15+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/Depositphotos_7451136_xl-2015.jpg https://www.fondazionebonadonna.eu/un-cambio-di-paradigma-nella-terapia-del-tumore-al-seno-metastatico/ 2021-09-20T08:00:16+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/en/a-paradigm-shift-in-the-treatment-of-metastatic-breast-cancer/ 2021-09-20T08:07:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/en/great-news-from-esmo-2021-results-from-the-most-important-clinical-studies/ 2021-09-22T10:44:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/AdobeStock_425085249_FGB.jpg https://www.fondazionebonadonna.eu/grandi-novita-da-esmo-2021-i-risultati-dagli-studi-clinici-di-maggior-rilievo/ 2021-09-22T10:46:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/AdobeStock_425085249_FGB.jpg https://www.fondazionebonadonna.eu/en/early-stage-breast-cancer-news-from-esmo/ 2021-09-24T08:00:39+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/Depositphotos_14095767_l-2015.jpg https://www.fondazionebonadonna.eu/tumore-al-seno-in-fase-iniziale-le-novita-da-esmo/ 2021-09-24T08:00:41+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/Depositphotos_14095767_l-2015.jpg https://www.fondazionebonadonna.eu/linibizione-di-cdk7-una-nuova-strategia-discussa-durante-esmo/ 2021-09-27T08:00:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_287373068_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/en/cdk7-inhibition-a-new-strategy-discussed-during-esmo/ 2021-09-27T08:24:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_287373068_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/mieloma-multiplo-risultati-incoraggianti-dallimmunoterapia-con-teclistamab/ 2021-10-04T08:00:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/AdobeStock_94084192_2500.jpg https://www.fondazionebonadonna.eu/en/multiple-myeloma-encouraging-data-for-an-immunotherapy-with-teclistamab/ 2021-10-04T08:25:24+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/AdobeStock_94084192_2500.jpg https://www.fondazionebonadonna.eu/diffondere-il-sapere-e-favorire-la-ricerca-due-obiettivi-della-fondazione/ 2021-10-11T08:00:25+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/fgb07.jpg https://www.fondazionebonadonna.eu/en/spreading-knowledge-and-promoting-research-the-two-foundations-main-objectives/ 2021-10-11T08:06:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/fgb07.jpg https://www.fondazionebonadonna.eu/dai-fibroblasti-associati-al-tumore-una-possibile-guida-per-la-terapia/ 2021-10-18T08:00:14+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_21053222.jpg https://www.fondazionebonadonna.eu/en/a-possible-guide-for-therapy-from-cancer-associated-fibroblasts/ 2021-10-18T08:17:56+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_21053222.jpg https://www.fondazionebonadonna.eu/i-meccanismi-alla-base-dellevasione-immunitaria-precoce-del-tumore-al-colon-retto/ 2021-10-25T07:51:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_66830781-scaled.jpeg https://www.fondazionebonadonna.eu/en/the-mechanisms-of-early-immune-escape-in-colorectal-cancer/ 2021-10-25T09:31:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_66830781-scaled.jpeg https://www.fondazionebonadonna.eu/tumore-al-seno-her2-in-fase-iniziale-leterogeneita-e-indicativa-di-resistenza-al-trattamento/ 2021-11-01T09:00:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_458604077-scaled.jpeg https://www.fondazionebonadonna.eu/immunopeptidomica-per-identificare-gli-antigeni-tumorali-non-canonici/ 2021-11-08T09:00:00+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_216470422.jpg https://www.fondazionebonadonna.eu/en/early-stage-her2-breast-cancer-her2-heterogeneity-predicts-treatment-resistance/ 2021-11-01T09:06:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_458604077-scaled.jpeg https://www.fondazionebonadonna.eu/en/immunopeptidomics-for-the-identification-of-noncanonical-tumor-antigens/ 2021-11-11T09:12:46+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_216470422.jpg https://www.fondazionebonadonna.eu/tumore-al-seno-triplo-negativo-ecco-le-cellule-decisive-per-la-risposta-ad-anti-pd-l1/ 2021-11-29T09:00:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/FGB_Depositphotos_112249332_xl-2015.jpg https://www.fondazionebonadonna.eu/tumore-al-seno-triplo-negativo-le-nuove-opzioni-di-terapia-e-le-strategie-future/ 2021-11-16T11:00:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/11/AdobeStock_281980599.jpg https://www.fondazionebonadonna.eu/en/triple-negative-breast-cancer-new-therapeutic-options-and-future-strategies/ 2021-11-16T11:02:56+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/11/AdobeStock_281980599.jpg https://www.fondazionebonadonna.eu/la-casistica-metabric-di-pazienti-con-tumore-al-seno-una-miniera-doro-di-dati-molecolari/ 2021-11-22T09:00:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/11/AdobeStock_221990325.jpg https://www.fondazionebonadonna.eu/en/breast-cancer-metabric-case-series-a-goldmine-of-molecular-data/ 2021-11-22T09:00:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/11/AdobeStock_221990325.jpg https://www.fondazionebonadonna.eu/en/triple-negative-breast-cancer-key-immune-cells-for-anti-pd-l1-response-revealed/ 2021-11-29T09:01:40+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/FGB_Depositphotos_112249332_xl-2015.jpg https://www.fondazionebonadonna.eu/la-ricerca-di-fondazione-michelangelo-al-san-antonio-breast-cancer-symposium-2021/ 2021-12-06T09:00:16+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/Depositphotos_7451136_xl-2015.jpg https://www.fondazionebonadonna.eu/tumore-al-seno-triplo-negativo-un-imaging-speciale-per-prevedere-la-risposta-allimmunoterapia/ 2021-12-07T15:00:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_287373068_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/en/research-from-michelangelo-foundation-at-san-antonio-breast-cancer-symposium-2021/ 2021-12-06T09:13:24+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/Depositphotos_7451136_xl-2015.jpg https://www.fondazionebonadonna.eu/en/triple-negative-breast-cancer-a-special-imaging-to-predict-immunotherapy-response/ 2021-12-07T15:07:39+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/Depositphotos_287373068_xl-2015_2500.jpg https://www.fondazionebonadonna.eu/tumore-al-seno-triplo-negativo-le-ultime-novita-dalle-ricerche-di-fondazione-michelangelo/ 2021-12-10T08:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/en/triple-negative-breast-cancer-the-latest-news-from-the-michelangelo-foundation-research/ 2021-12-10T08:01:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/elacestrant-aumenta-la-sopravvivenza-libera-da-progressione-in-pazienti-con-tumore-al-seno-metastatico-er-her2/ 2021-12-20T09:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_458604077-scaled.jpeg https://www.fondazionebonadonna.eu/en/elacestrant-increases-progression-free-survival-in-patients-with-metastatic-er-her2-breast-cancer/ 2021-12-20T09:04:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_458604077-scaled.jpeg https://www.fondazionebonadonna.eu/buoni-risultati-con-datopotamab-deruxtecan-nel-tumore-mammario-triplo-negativo/ 2021-12-27T09:00:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/12/AdobeStock_237044017-scaled.jpeg https://www.fondazionebonadonna.eu/en/positive-response-with-datopotamab-deruxtecan-in-triple-negative-breast-cancer/ 2021-12-27T09:10:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/12/AdobeStock_237044017-scaled.jpeg https://www.fondazionebonadonna.eu/come-prevedere-la-risposta-del-tumore-mammario-alle-terapie/ 2022-01-10T10:08:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_216470422.jpg https://www.fondazionebonadonna.eu/en/how-to-predict-breast-cancer-therapy-response/ 2022-01-10T11:05:19+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_216470422.jpg https://www.fondazionebonadonna.eu/tumore-del-polmone-possibili-vantaggi-associando-un-inibitore-di-egfr-tk-a-patritumab-deruxtecan/ 2022-01-17T09:00:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_179300782.jpg https://www.fondazionebonadonna.eu/melanoma-avanzato-buoni-risultati-con-relatlimab-e-nivolumab/ 2022-01-24T09:00:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_261932205.jpg https://www.fondazionebonadonna.eu/en/lung-cancer-benefits-from-the-combination-of-egfr-tk-inhibitors-and-patritumab-deruxtecan/ 2022-01-17T09:10:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_179300782.jpg https://www.fondazionebonadonna.eu/en/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab/ 2022-01-24T09:02:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_261932205.jpg https://www.fondazionebonadonna.eu/buoni-risultati-con-polatuzumab-vedotin-contro-il-linfoma/ 2022-01-31T09:00:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_226376958.jpg https://www.fondazionebonadonna.eu/dabrafenib-e-trametinib-per-il-tumore-anaplastico-alla-tiroide/ 2022-02-14T09:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_259168782.jpg https://www.fondazionebonadonna.eu/en/encouraging-results-with-polatuzumab-vedotin-in-lymphoma-patients/ 2022-01-31T09:27:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_226376958.jpg https://www.fondazionebonadonna.eu/en/two-female-researchers-win-the-first-edition-of-the-fellowship-named-after-gianni-bonadonna/ 2022-02-07T10:55:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/due-ricercatrici-vincono-la-prima-edizione-del-bando-per-borse-di-studio-intitolato-a-gianni-bonadonna/ 2022-02-07T10:56:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/en/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer/ 2022-02-14T09:11:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_259168782.jpg https://www.fondazionebonadonna.eu/tumore-mammario-her2-e-er-buoni-risultati-con-trastuzumab-pertuzumab-e-palbociclib/ 2022-02-21T09:00:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_302042936.jpeg https://www.fondazionebonadonna.eu/en/her2-and-er-breast-cancer-promising-results-with-trastuzumab-pertuzumab-and-palbociclib/ 2022-02-21T09:03:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_302042936.jpeg https://www.fondazionebonadonna.eu/tumore-mammario-triplo-negativo-nuovi-dati-dallo-studio-neotrip-di-fondazione-michelangelo/ 2022-02-28T09:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_235871936.jpeg https://www.fondazionebonadonna.eu/en/triple-negative-breast-cancer-new-data-from-michelangelo-foundations-neotrip-trial/ 2022-02-28T09:15:39+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_235871936.jpeg https://www.fondazionebonadonna.eu/la-degradazione-proteica-mirata-per-agire-su-bersagli-finora-ritenuti-impossibili/ 2022-03-07T09:00:20+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_122944229.jpeg https://www.fondazionebonadonna.eu/en/targeted-protein-degradation-to-tackle-undruggable-targets/ 2022-03-07T09:05:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_122944229.jpeg https://www.fondazionebonadonna.eu/gli-inibitori-della-n-glicosilazione-una-nuova-strategia-di-cura/ 2022-03-14T09:00:50+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/03/shutterstock_536117293.jpg https://www.fondazionebonadonna.eu/en/a-first-in-human-research-protocol-investigates-the-effects-of-membrane-proteins-glycosylation-inhibitors/ 2022-03-14T09:01:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/03/shutterstock_536117293.jpg https://www.fondazionebonadonna.eu/inibire-mek-per-potenziare-la-chemio-immunoterapia/ 2022-03-21T09:00:48+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_179300782.jpg https://www.fondazionebonadonna.eu/pyrotinib-e-capecitabina-nel-tumore-mammario-con-metastasi-cerebrali/ 2022-04-11T08:00:46+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/en/mek-inhibition-enhances-chemoimmunotherapy/ 2022-03-21T09:29:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_179300782.jpg https://www.fondazionebonadonna.eu/tumore-mammario-un-meccanismo-per-superare-la-resistenza-a-terapie-endocrine-e-farmaci-anti-er-e-anti-her2/ 2022-03-28T08:00:25+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_235871936.jpeg https://www.fondazionebonadonna.eu/un-nuovo-approccio-per-affrontare-i-tumori-enhancer-addicted/ 2022-04-25T08:00:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/lenvatinib-e-pembrolizumab-efficaci-nel-tumore-allendometrio/ 2022-04-04T08:00:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_75095343.jpeg https://www.fondazionebonadonna.eu/individuati-alcuni-meccanismi-pro-tumorali-nella-leucemia/ 2022-04-18T08:00:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_276496579.jpeg https://www.fondazionebonadonna.eu/en/breast-cancer-a-mechanism-to-bypass-anti-er-and-anti-her2-resistance/ 2022-03-28T08:08:05+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_235871936.jpeg https://www.fondazionebonadonna.eu/en/lenvatinib-and-pembrolizumab-efficacy-in-endometrial-cancer/ 2022-04-04T08:02:20+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_75095343.jpeg https://www.fondazionebonadonna.eu/en/pyrotinib-plus-capecitabine-in-breast-cancer-with-brain-metastases/ 2022-04-11T08:25:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/en/pro-tumorigenic-mechanisms-of-leukaemia/ 2022-04-18T08:05:16+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_276496579.jpeg https://www.fondazionebonadonna.eu/en/un-nuovo-approccio-per-affrontare-i-tumori-enhancer-addicted/ 2022-04-25T08:26:01+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/una-nuova-piattaforma-di-screening-per-individuare-possibili-inibitori-di-kras/ 2022-05-02T08:00:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_313579636.jpeg https://www.fondazionebonadonna.eu/en/a-new-screening-platform-to-discover-novel-kras-inhibitors/ 2022-05-02T08:44:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_313579636.jpeg https://www.fondazionebonadonna.eu/le-strutture-del-microambiente-tumorale-nel-tumore-mammario-sono-associate-allesito-clinico/ 2022-05-09T08:00:00+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_228429236.jpeg https://www.fondazionebonadonna.eu/attivita-e-sicurezza-di-pemigatinib-inibitore-selettivo-di-fgfr-1-3/ 2022-05-16T08:00:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_297613181.jpg https://www.fondazionebonadonna.eu/en/breast-tumor-microenvironment-structures-are-associated-with-clinical-outcomes/ 2022-05-09T08:14:17+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_228429236.jpeg https://www.fondazionebonadonna.eu/en/safety-and-activity-of-the-selective-fgfr-1-3-inhibitor-pemigatinib/ 2022-05-16T08:11:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_297613181.jpg https://www.fondazionebonadonna.eu/promettente-attivita-antitumorale-per-rucaparib-e-sacituzumab-govitecan/ 2022-05-23T08:00:39+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_361549626.jpeg https://www.fondazionebonadonna.eu/en/promising-antitumor-activity-of-rucaparib-and-sacituzumab-govitecan/ 2022-05-23T08:06:56+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_361549626.jpeg https://www.fondazionebonadonna.eu/risultati-promettenti-di-alpelisib-e-olaparib-nel-tumore-mammario-triplo-negativo-avanzato/ 2022-05-30T08:00:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_302042936.jpeg https://www.fondazionebonadonna.eu/en/promising-results-with-alpesilib-plus-olaparib-in-advanced-triple-negative-breast-cancer/ 2022-05-30T08:11:01+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_302042936.jpeg https://www.fondazionebonadonna.eu/regressione-del-tumore-mammario-con-un-anticorpo-trispecifico/ 2022-06-06T08:00:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_182073761.jpeg https://www.fondazionebonadonna.eu/en/breast-cancer-regression-with-a-trispecific-antibody/ 2022-06-06T08:12:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_182073761.jpeg https://www.fondazionebonadonna.eu/primi-incoraggianti-risultati-con-le-car-t-e-pembrolizumab-nel-mesotelioma-pleurico/ 2022-06-13T08:00:39+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_179300782.jpg https://www.fondazionebonadonna.eu/en/first-positive-results-with-a-car-t-therapy-plus-pembrolizumab-in-malignant-pleural-mesothelioma/ 2022-06-13T08:01:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_179300782.jpg https://www.fondazionebonadonna.eu/una-rivoluzione-nella-terapia-del-tumore-al-seno-metastatico/ 2022-06-20T08:00:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_239039608_XL.jpg https://www.fondazionebonadonna.eu/en/a-breakthrough-in-the-treatment-of-advanced-breast-cancer/ 2022-06-20T08:06:41+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_239039608_XL.jpg https://www.fondazionebonadonna.eu/neratinib-e-fulvestrant-sono-attivi-nel-tumore-mammario-metastatico-con-her2-mutato/ 2022-07-04T08:00:57+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_431587103.jpeg https://www.fondazionebonadonna.eu/olaparib-efficace-in-pazienti-con-tumore-mammario-in-stadio-precoce-con-mutazioni-di-brca/ 2022-06-27T08:00:01+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/en/activity-of-olaparib-in-patients-with-brca-mutated-early-breast-cancer/ 2022-06-27T08:01:23+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/lefficacia-di-nivolumab-in-terapia-neoadiuvante-nel-tumore-al-polmone-resecabile/ 2022-07-11T08:00:40+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/48100511.jpg https://www.fondazionebonadonna.eu/un-nuovo-farmaco-immuno-coniugato-per-il-tumore-mammario-metastatico/ 2022-07-18T08:00:06+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/AdobeStock_94084192_2500.jpg https://www.fondazionebonadonna.eu/en/neratinib-and-fulvestrant-are-active-for-her2-mutated-metastatic-breast-cancerneratinib-and-fulvestrant-are-active-for-her2-mutated-metastatic-breast-cancer/ 2022-07-04T08:02:33+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_431587103.jpeg https://www.fondazionebonadonna.eu/en/efficacy-of-nivolumab-as-neoadjuvant-therapy-in-resectable-lung-cancer/ 2022-07-11T08:22:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/48100511.jpg https://www.fondazionebonadonna.eu/en/a-novel-antibody-drug-conjugate-for-metastatic-breast-cancer-patients/ 2022-07-18T08:06:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/AdobeStock_94084192_2500.jpg https://www.fondazionebonadonna.eu/benefici-clinici-durevoli-nel-tumore-al-polmone-con-un-inibitore-di-krasg12c/ 2022-07-25T08:00:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_21053222.jpg https://www.fondazionebonadonna.eu/superati-i-100-000-pazienti-nel-progetto-genie-di-aacr/ 2022-08-01T08:00:42+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/en/durable-clinical-benefits-in-lung-cancer-with-a-krasg12c-inhibitor/ 2022-07-25T08:11:44+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_21053222.jpg https://www.fondazionebonadonna.eu/en/more-than-100-000-cases-in-the-aacr-project-genie/ 2022-08-01T08:08:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/i-vaccini-per-i-tumori-presente-e-futuro/ 2022-08-29T08:00:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/FGB_Depositphotos_112249332_xl-2015.jpg https://www.fondazionebonadonna.eu/amcenestrant-in-donne-in-post-menopausa-con-tumore-mammario-avanzato-er-her2/ 2022-08-22T12:45:33+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_302042936.jpeg https://www.fondazionebonadonna.eu/en/amcenestrant-in-post-menopausal-women-with-er-positive-her2-negative-advanced-breast-cancer/ 2022-08-22T12:45:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_302042936.jpeg https://www.fondazionebonadonna.eu/en/cancer-vaccines-present-and-future/ 2022-08-29T08:05:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/07/FGB_Depositphotos_112249332_xl-2015.jpg https://www.fondazionebonadonna.eu/risultati-positivi-con-pembrolizumab-nel-tumore-mammario-triplo-negativo-avanzato/ 2022-09-05T08:00:58+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_106932502_XL.jpg https://www.fondazionebonadonna.eu/en/positive-results-with-pembrolizumab-in-advanced-triple-negative-breast-cancer/ 2022-09-05T08:20:05+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_106932502_XL.jpg https://www.fondazionebonadonna.eu/benefici-con-pralsetinib-in-pazienti-con-fusioni-ret/ 2022-09-26T08:00:28+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_143340083.jpeg https://www.fondazionebonadonna.eu/iniziato-il-trattamento-dei-pazienti-nel-primo-studio-con-inibitori-selettivi-della-n-glicosilazione/ 2022-09-14T10:00:25+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/03/shutterstock_536117293.jpg https://www.fondazionebonadonna.eu/en/dosing-of-first-three-patients-in-the-first-in-human-study-with-selective-n-glycosylation-inhibitors/ 2022-09-14T10:09:14+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/03/shutterstock_536117293.jpg https://www.fondazionebonadonna.eu/i-risultati-di-durvalumab-in-terapia-neoadiuvante-nel-tumore-mammario-triplo-negativo-il-commento-degli-esperti/ 2022-09-21T09:30:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_458604077-scaled.jpeg https://www.fondazionebonadonna.eu/en/outcomes-of-neoadjuvant-durvalumab-in-triple-negative-breast-cancer-experts-comment/ 2022-09-21T09:33:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_458604077-scaled.jpeg https://www.fondazionebonadonna.eu/en/benefits-of-pralsetinib-in-patients-with-ret-fusions/ 2022-09-26T08:01:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_143340083.jpeg https://www.fondazionebonadonna.eu/limmunoterapia-neoadiuvante-un-approccio-promettente-per-melanoma-e-tumore-al-colon/ 2022-10-03T08:00:02+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_239039608_XL.jpg https://www.fondazionebonadonna.eu/en/neoadjuvant-immunotherapy-as-a-promising-approach-in-melanoma-and-colon-cancer/ 2022-10-03T08:25:19+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_239039608_XL.jpg https://www.fondazionebonadonna.eu/pembrolizumab-come-terapia-adiuvante-dopo-la-nefrectomia-in-pazienti-con-carcinoma-renale/ 2022-10-10T08:00:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_106932502_XL.jpg https://www.fondazionebonadonna.eu/en/pembrolizumab-as-post-nephrectomy-adjuvant-therapy-in-renal-cell-carcinoma/ 2022-10-10T08:23:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_106932502_XL.jpg https://www.fondazionebonadonna.eu/test-genomici-per-selezionare-la-terapia-nel-tumore-mammario-metastatico/ 2022-10-17T08:00:00+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/i-benefici-clinici-di-un-targeting-precoce-delle-mutazioni-di-esr1/ 2022-10-24T08:00:56+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_447619286.jpg https://www.fondazionebonadonna.eu/trastuzumab-deruxtecan-nel-tumore-mammario-her2-con-metastasi-cerebrali/ 2022-10-31T09:00:10+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_228429236.jpeg https://www.fondazionebonadonna.eu/en/treatment-selection-with-genomics-for-metastatic-breast-cancer/ 2022-10-17T08:04:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/en/clinical-benefits-of-an-early-therapeutic-targeting-of-esr1-mutation/ 2022-10-24T09:16:39+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_447619286.jpg https://www.fondazionebonadonna.eu/en/trastuzumab-deruxtecan-in-her2-breast-cancer-with-brain-metastases/ 2022-10-31T09:01:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_228429236.jpeg https://www.fondazionebonadonna.eu/risultati-promettenti-con-olaparib-nel-tumore-mammario-precoce/ 2022-11-07T09:00:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1138405349.jpg https://www.fondazionebonadonna.eu/en/olaparib-shows-promising-results-in-early-breast-cancer/ 2022-11-09T08:38:33+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1138405349.jpg https://www.fondazionebonadonna.eu/talazoparib-in-monoterapia-nel-tumore-mammario-avanzato/ 2022-11-14T09:00:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/en/talazoparib-as-monotherapy-in-advanced-breast-cancer/ 2022-11-14T09:01:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/06/FGB_28_06.jpg https://www.fondazionebonadonna.eu/abemaciclib-e-pembrolizumab-nel-tumore-mammario-metastatico-er-her2/ 2022-11-28T09:00:03+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1356345613_2500.jpg https://www.fondazionebonadonna.eu/la-combinazione-di-olaparib-e-radioterapia-nel-tumore-mammario-triplo-negativo/ 2022-12-05T09:00:24+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1254386936_2500.jpg https://www.fondazionebonadonna.eu/come-selezionare-le-pazienti-con-tumore-mammario-od-ovarico-da-trattare-con-olaparib/ 2022-11-21T09:00:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-486784816_2500.jpg https://www.fondazionebonadonna.eu/en/how-to-select-patients-with-breast-and-ovarian-cancer-for-the-treatment-with-olaparib/ 2022-11-21T09:01:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-486784816_2500.jpg https://www.fondazionebonadonna.eu/en/abemaciclib-and-pembrolizumab-in-hr-her2-metastatic-breast-cancer/ 2022-11-28T09:05:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1356345613_2500.jpg https://www.fondazionebonadonna.eu/en/combination-of-olaparib-and-radiotherapy-in-triple-negative-breast-cancer/ 2022-12-05T09:02:02+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1254386936_2500.jpg https://www.fondazionebonadonna.eu/fondazione-michelangelo-al-san-antonio-breast-cancer-symposium/ 2022-12-12T09:00:54+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/Depositphotos_7451136_xl-2015.jpg https://www.fondazionebonadonna.eu/en/fondazione-michelangelo-at-the-san-antonio-breast-cancer-symposium/ 2022-12-12T09:02:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/09/Depositphotos_7451136_xl-2015.jpg https://www.fondazionebonadonna.eu/lanticorpo-bispecifico-zanidatamab-in-tumori-solidi-che-esprimono-her2/ 2022-12-19T09:00:56+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/en/the-bispecific-antibody-zanidatamab-in-her2-expressing-solid-tumors/ 2022-12-19T09:03:02+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/survaxm-e-temozolomide-in-terapia-adiuvante-nel-glioblastoma-di-nuova-diagnosi/ 2023-01-02T09:00:42+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/en/survaxm-plus-adjuvant-temozolomide-in-newly-diagnosed-glioblastoma/ 2023-01-02T09:05:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/trastuzumab-deruxtecan-nel-tumore-mammario-metastatico-her2/ 2023-01-09T09:00:06+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1295015738_2500.jpg https://www.fondazionebonadonna.eu/risultati-promettenti-con-lurbinectedina-nel-sarcoma-di-ewing-recidivante/ 2023-01-16T09:00:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_297613181.jpg https://www.fondazionebonadonna.eu/en/trastuzumab-deruxtecan-in-her2-metastatic-breast-cancer/ 2023-01-09T09:00:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1295015738_2500.jpg https://www.fondazionebonadonna.eu/en/promising-results-with-lurbinectedin-in-relapsed-ewing-sarcoma/ 2023-01-16T09:10:54+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_297613181.jpg https://www.fondazionebonadonna.eu/inibitori-parp-nel-carcinoma-prostatico-avanzato-determinare-le-alterazioni-dei-geni-hrr-e-fondamentale-per-i-risultati/ 2023-01-23T09:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_122944229.jpeg https://www.fondazionebonadonna.eu/en/parp-inhibitors-in-advanced-prostate-cancer-determining-hrr-genes-alterations-is-crucial-for-outcomes/ 2023-01-23T09:08:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_122944229.jpeg https://www.fondazionebonadonna.eu/benefici-clinici-di-futibatinib-nel-colangiocarcinoma-intraepatico/ 2023-01-30T09:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_250915764_XL.jpg https://www.fondazionebonadonna.eu/en/clinical-benefits-with-futibatinib-in-intra-hepatic-cholangiocarcinoma/ 2023-01-30T09:08:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_250915764_XL.jpg https://www.fondazionebonadonna.eu/lapprendimento-federato-per-predire-la-risposta-alla-chemioterapia-nel-tumore-mammario-triplo-negativo/ 2023-02-06T09:00:11+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-839295568_2500.jpg https://www.fondazionebonadonna.eu/trastuzumab-deruxtecan-in-tumori-gastrici-avanzati/ 2023-02-20T09:00:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1218792909.jpg https://www.fondazionebonadonna.eu/en/federated-learning-to-predicting-chemotherapy-response-in-triple-negative-breast-cancer/ 2023-02-06T09:01:14+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-839295568_2500.jpg https://www.fondazionebonadonna.eu/una-giovane-ematologa-e-ricercatrice-ottiene-una-borsa-di-studio-nellambito-della-seconda-edizione-del-bando-intitolato-alla-memoria-di-gianni-bonadonna/ 2023-02-13T09:00:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/en/a-young-hematologist-and-researcher-is-awarded-a-fellowship-in-the-second-edition-of-the-call-dedicated-to-the-memory-of-gianni-bonadonna/ 2023-02-13T09:07:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/en/trastuzumab-deruxtecan-in-advanced-gastric-tumors/ 2023-02-20T09:09:33+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1218792909.jpg https://www.fondazionebonadonna.eu/avelumab-in-combinazione-alla-chemioterapia-nel-tumore-dellendometrio-avanzato-o-recidivante/ 2023-02-27T09:00:01+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/olaparib-nel-tumore-mammario-metastatico-her-2-negativo-con-mutazioni-di-brca/ 2023-03-06T09:00:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1295015738_2500.jpg https://www.fondazionebonadonna.eu/la-dieta-mediterranea-puo-migliorare-lefficacia-dellimmunoterapia-nel-melanoma-avanzato/ 2023-03-13T09:00:23+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_261932205.jpg https://www.fondazionebonadonna.eu/en/avelumab-added-to-chemotherapy-in-advanced-or-recurrent-endometrial-cancer/ 2023-02-27T09:00:34+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/dabrafenib-e-trametinib-nel-tumore-della-tiroide-anaplastico-avanzato/ 2023-03-20T09:00:10+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_259168782.jpg https://www.fondazionebonadonna.eu/en/olaparib-in-brca-mutated-her-2-negative-metastatic-breast-cancer/ 2023-03-06T09:12:46+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1295015738_2500.jpg https://www.fondazionebonadonna.eu/en/mediterranean-diet-could-improve-efficacy-of-immunotherapy-in-advanced-melanoma/ 2023-03-13T09:07:46+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_261932205.jpg https://www.fondazionebonadonna.eu/en/dabrafenib-and-trametinib-in-anaplastic-advanced-thyroid-cancer/ 2023-03-20T09:00:52+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_259168782.jpg https://www.fondazionebonadonna.eu/al-via-lo-studio-alphabet-sul-tumore-mammario/ 2023-03-27T08:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/en/the-alphabet-study-on-breast-cancer-is-enrolling-patients/ 2023-03-27T08:04:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/tumore-al-colon-retto-trattato-con-pembrolizumab-gli-effetti-del-sito-di-metastasi/ 2023-04-03T08:00:39+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1319439468.jpg https://www.fondazionebonadonna.eu/osimertinib-in-terapia-adiuvante-nel-carcinoma-polmonare-non-a-piccole-cellule/ 2023-04-11T08:00:59+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/48100511.jpg https://www.fondazionebonadonna.eu/la-sensibilita-allacido-retinoico-nel-tumore-mammario/ 2023-04-17T08:00:15+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1356345613_2500.jpg https://www.fondazionebonadonna.eu/en/metastatic-site-and-survival-in-colorectal-cancer-treated-with-pembrolizumab/ 2023-04-03T08:05:23+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1319439468.jpg https://www.fondazionebonadonna.eu/pembrolizumab-in-terapia-neoadiuvante-adiuvante-o-solo-adiuvante-nel-melanoma/ 2023-04-24T08:00:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1281446789.jpg https://www.fondazionebonadonna.eu/sotorasib-o-docetaxel-nel-carcinoma-polmonare-non-a-piccole-cellule-con-mutazione-krasg12c/ 2023-05-02T08:00:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-696241690.jpg https://www.fondazionebonadonna.eu/il-valore-prognostico-del-ctdna-nel-tumore-mammario-triplo-negativo/ 2023-05-08T08:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1254386936_2500.jpg https://www.fondazionebonadonna.eu/una-combinazione-di-immunoterapia-per-il-tumore-del-colon-retto/ 2023-05-15T08:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1218792909.jpg https://www.fondazionebonadonna.eu/en/adjuvant-osimertinib-in-non-small-cell-lung-cancer/ 2023-04-11T08:08:31+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/48100511.jpg https://www.fondazionebonadonna.eu/en/retinoic-acid-sensitivity-in-breast-cancer/ 2023-04-17T08:03:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1356345613_2500.jpg https://www.fondazionebonadonna.eu/en/neoadjuvant-adjuvant-or-adjuvant-pembrolizumab-in-melanoma/ 2023-04-24T08:07:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1281446789.jpg https://www.fondazionebonadonna.eu/en/sotorasib-or-docetaxel-in-krasg12c-mutated-non-small-cell-lung-cancer/ 2023-05-02T08:04:29+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-696241690.jpg https://www.fondazionebonadonna.eu/en/prognostic-value-of-ctdna-in-triple-negative-breast-cancer/ 2023-05-08T08:07:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1254386936_2500.jpg https://www.fondazionebonadonna.eu/en/an-immunotherapy-combination-for-colorectal-cancer/ 2023-05-15T08:04:35+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1218792909.jpg https://www.fondazionebonadonna.eu/olaparib-nel-tumore-alla-prostata-metastatico-con-mutazioni-brca1-2/ 2023-05-29T08:00:34+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-526212629.jpg https://www.fondazionebonadonna.eu/le-borse-di-studio-in-memoria-di-gianni-bonadonna-unoccasione-per-crescere/ 2023-05-19T10:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/en/the-fellowships-in-memory-of-gianni-bonadonna-an-opportunity-for-growth/ 2023-05-19T10:16:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/en/olaparib-in-metastatic-prostate-cancer-with-brca1-2-mutations/ 2023-05-29T08:08:05+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-526212629.jpg https://www.fondazionebonadonna.eu/atezolizumab-e-carboplatino-nel-tumore-alla-mammella-lobulare-metastatico/ 2023-06-05T08:00:46+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1138405349.jpg https://www.fondazionebonadonna.eu/en/atezolizumab-and-carboplatin-in-metastatic-lobular-breast-cancer/ 2023-06-05T08:02:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1138405349.jpg https://www.fondazionebonadonna.eu/gli-effetti-delle-co-mutazioni-sullefficacia-degli-inibitori-kras-g12c-nel-carcinoma-polmonare-non-a-piccole-cellule-avanzato/ 2023-06-12T08:00:15+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_250915764_XL.jpg https://www.fondazionebonadonna.eu/en/co-mutations-effects-on-kras-g12c-inhibitor-efficacy-in-advanced-non-small-cell-lung-cancer/ 2023-06-12T08:04:11+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_250915764_XL.jpg https://www.fondazionebonadonna.eu/un-metodo-per-superare-le-resistenze-alla-terapia-mirata-a-fgfr-nel-colangiocarcinoma/ 2023-06-19T08:00:54+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/uninattesa-vulnerabilita-nel-tumore-alla-mammella-triplo-negativo-puo-diventare-un-bersaglio/ 2023-07-10T08:00:42+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-696241690.jpg https://www.fondazionebonadonna.eu/trastuzumab-deruxtecan-in-pazienti-con-tumore-alla-mammella-her2-metastatico-i-risultati-da-destiny-breast02/ 2023-06-26T08:00:00+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1013103082.jpg https://www.fondazionebonadonna.eu/lattivita-di-tucatinib-e-trastuzumab-nel-tumore-del-colon-retto-metastatico/ 2023-07-03T08:00:54+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1319439468.jpg https://www.fondazionebonadonna.eu/trifluridina-tipiracil-e-bevacizumab-nel-tumore-metastatico-del-colon-retto/ 2023-07-17T08:00:02+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_408276810_XL.jpg https://www.fondazionebonadonna.eu/en/a-way-to-overcome-resistance-to-fgfr-therapy-in-cholangiocarcinoma/ 2023-06-19T08:03:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/en/trastuzumab-deruxtecan-in-patients-with-her2-metastatic-breast-cancer-results-from-destiny-breast02/ 2023-06-26T08:02:02+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1013103082.jpg https://www.fondazionebonadonna.eu/en/activity-of-tucatinib-plus-trastuzumab-in-metastatic-colorectal-cancer/ 2023-07-03T08:03:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1319439468.jpg https://www.fondazionebonadonna.eu/en/targeting-an-unexpected-vulnerability-p53-inactivated-triple-negative-breast-cancer/ 2023-07-10T08:02:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-696241690.jpg https://www.fondazionebonadonna.eu/cabozantinib-nivolumab-e-ipilimumab-nel-carcinoma-a-cellule-renali-avanzato/ 2023-07-24T08:00:29+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1013103082.jpg https://www.fondazionebonadonna.eu/un-nuovo-inibitore-di-fgfr2-con-attivita-sulle-diverse-alterazioni-di-fgfr2/ 2023-07-31T08:00:10+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_505085576_XL.jpg https://www.fondazionebonadonna.eu/en/trifluridine-tipiracil-plus-bevacizumab-in-metastatic-colorectal-cancer/ 2023-07-17T08:03:00+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_408276810_XL.jpg https://www.fondazionebonadonna.eu/en/cabozantinib-nivolumab-and-ipilimumab-in-advanced-renal-cell-carcinoma/ 2023-07-24T08:09:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1013103082.jpg https://www.fondazionebonadonna.eu/i-determinanti-della-risposta-a-trastuzumab-deruxtecan-nel-tumore-mammario-metastatico/ 2023-08-07T08:00:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/11/AdobeStock_221990325.jpg https://www.fondazionebonadonna.eu/camrelizumab-e-rivoracemib-nel-carcinoma-epatocellulare-non-operabile/ 2023-08-21T08:00:42+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1167361072.jpg https://www.fondazionebonadonna.eu/en/a-new-fgfr2-inhibitor-with-activity-across-fgfr2-alterations/ 2023-07-31T08:09:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_505085576_XL.jpg https://www.fondazionebonadonna.eu/en/camrelizumab-plus-rivoracenib-for-unresectable-hepatocellular-carcinoma/ 2023-08-21T08:00:52+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1167361072.jpg https://www.fondazionebonadonna.eu/en/determinants-of-trastuzumab-deruxtecan-response-in-metastatic-breast-cancer/ 2023-08-07T08:01:31+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/11/AdobeStock_221990325.jpg https://www.fondazionebonadonna.eu/atezolizumab-in-terapia-adiuvante-dopo-la-chemioterapia-nel-tumore-polmonare-non-a-piccole-cellule/ 2023-09-04T08:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/48100511.jpg https://www.fondazionebonadonna.eu/dostarlimab-nel-tumore-dellendometrio-primario-avanzato-o-recidivante/ 2023-09-11T08:00:01+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/en/dostarlimab-in-primary-advanced-or-recurrent-endometrial-cancer/ 2023-09-11T08:00:02+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/en/atezolizumab-after-chemotherapy-in-resected-non-small-cell-lung-cancer/ 2023-09-04T08:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/48100511.jpg https://www.fondazionebonadonna.eu/linibizione-di-shp2-per-superare-la-resistenza-alle-terapie-a-bersaglio-molecolare/ 2023-09-18T08:00:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/en/shp2-inhibition-to-overcome-resistance-to-targeted-therapies/ 2023-09-18T08:00:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/en/is-it-possible-to-predict-the-efficacy-of-immunotherapy-in-triple-negative-breast-cancer/ 2023-09-08T10:00:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Nature.jpg https://www.fondazionebonadonna.eu/e-possibile-predire-lefficacia-dellimmunoterapia-nei-tumori-della-mammella-triplo-negativi/ 2023-09-08T10:00:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Nature.jpg https://www.fondazionebonadonna.eu/selpercatinib-nei-tumori-tiroidei-e-non-solo/ 2023-10-02T08:00:48+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_297613181.jpg https://www.fondazionebonadonna.eu/neratinib-fulvestrant-e-trastuzumab-nel-tumore-mammario-metastatico-con-mutazioni-di-her2/ 2023-10-09T08:00:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_246093832_XL.jpg https://www.fondazionebonadonna.eu/en/selpercatinib-in-thyroid-and-other-tumors/ 2023-10-02T08:00:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_297613181.jpg https://www.fondazionebonadonna.eu/un-ruolo-rilevante-nei-tumori-per-la-proteina-tau/ 2023-09-25T08:00:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_250900006_XL.jpg https://www.fondazionebonadonna.eu/en/a-relevant-role-for-tau-protein-in-cancer/ 2023-09-25T08:00:20+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_250900006_XL.jpg https://www.fondazionebonadonna.eu/en/neratinib-fulvestrant-and-trastuzumab-in-her2-mutant-metastatic-breast-cancer/ 2023-10-13T10:25:06+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_246093832_XL.jpg https://www.fondazionebonadonna.eu/una-piattaforma-web-per-aiutare-nella-ricerca-e-sviluppo-clinico-di-farmaci-anticorpo-coniugati/ 2023-10-16T08:00:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_216470422.jpg https://www.fondazionebonadonna.eu/ipilimumab-con-e-senza-nivolumab-nel-melanoma-metastatico-refrattario/ 2023-10-23T08:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_180844752_XL.jpg https://www.fondazionebonadonna.eu/sacituzumab-govitecan-nel-tumore-mammario-metastatico-er-her2/ 2023-10-30T09:00:17+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_216414188_XL.jpg https://www.fondazionebonadonna.eu/en/ipilimumab-with-or-without-nivolumab-in-refractory-metastatic-melanoma/ 2023-10-23T08:00:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_180844752_XL.jpg https://www.fondazionebonadonna.eu/en/the-analysis-of-thousands-of-cancer-and-normal-tissue-gene-expression-profiles-can-guide-clinical-development-of-antibody-drug-coniugates-in-the-right-patient-population/ 2023-10-16T08:14:28+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_216470422.jpg https://www.fondazionebonadonna.eu/en/sacituzumab-govitecan-in-er-her2-metastatic-breast-cancer/ 2023-10-30T09:00:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_216414188_XL.jpg https://www.fondazionebonadonna.eu/dati-da-una-casistica-di-tumori-mammari-che-perdono-i-recettori-per-gli-estrogeni-alla-recidiva-metastatica/ 2023-11-06T09:00:03+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_274592970_XL.jpg https://www.fondazionebonadonna.eu/en/clinical-outcomes-of-luminal-like-breast-cancers-with-estrogen-receptors-loss-at-metastatic-relapse/ 2023-11-06T09:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_274592970_XL.jpg https://www.fondazionebonadonna.eu/pembrolizumab-ed-enfortumab-vedotin-nel-tumore-alla-vescica/ 2023-11-20T09:00:41+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/i-serd-orali-nel-tumore-mammario-metastatico-er-her2-unanalisi-sui-sottogruppi-con-e-senza-mutazioni-di-esr1/ 2023-11-27T09:00:02+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_11045917_XL.jpg https://www.fondazionebonadonna.eu/divarasib-in-tumori-solidi-con-mutazione-di-kras-g12c/ 2023-12-04T09:00:28+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_340781962_XL.jpg https://www.fondazionebonadonna.eu/benefici-con-nimotuzumab-e-gemcitabina-nel-tumore-al-pancreas-senza-mutazioni-di-k-ras/ 2023-12-11T09:00:28+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-526212629.jpg https://www.fondazionebonadonna.eu/patritumab-deruxtecan-nel-tumore-mammario-metastatico-che-esprime-her3/ 2023-12-18T09:00:20+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_425875532_XL.jpg https://www.fondazionebonadonna.eu/en/benefits-with-nimotuzumab-plus-gemcitabine-in-k-ras-wild-type-pancreatic-cancer/ 2023-12-11T09:00:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-526212629.jpg https://www.fondazionebonadonna.eu/en/divarasib-in-solid-tumors-with-a-kras-g12c-mutation/ 2023-12-04T09:00:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_340781962_XL.jpg https://www.fondazionebonadonna.eu/en/pembrolizumab-plus-enfortumab-vedotin-in-bladder-cancer/ 2023-11-20T09:00:57+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/en/oral-serds-in-er-her2-metastatic-breast-cancer-an-analysis-of-esr1-wild-type-mutant-subgroups/ 2023-11-27T09:00:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_11045917_XL.jpg https://www.fondazionebonadonna.eu/en/patritumab-deruxtecan-in-her-3-expressing-metastatic-breast-cancer/ 2023-12-18T09:00:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_425875532_XL.jpg https://www.fondazionebonadonna.eu/en/molecular-features-of-high-proliferation-low-er-related-signaling-breast-cancers-suggest-more-effective-therapeutic-strategies/ 2023-11-13T09:00:16+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/11/BJC.jpg https://www.fondazionebonadonna.eu/le-caratteristiche-molecolari-di-un-sottogruppo-di-tumori-mammari-particolarmente-aggressivi-possono-suggerire-le-strategie-terapeutiche-piu-efficaci/ 2023-11-13T09:36:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/11/BJC.jpg https://www.fondazionebonadonna.eu/inavosilib-nel-tumore-mammario-localmente-avanzato-o-metastatico-hr-her2/ 2024-01-08T11:00:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_11045917_XL.jpg https://www.fondazionebonadonna.eu/ribociclib-e-terapia-ormonale-migliorano-gli-esiti-nel-tumore-mammario-precoce-hr-her2/ 2024-01-15T09:00:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1273858064.jpg https://www.fondazionebonadonna.eu/en/ribociclib-plus-hormone-therapy-improves-outcomes-in-early-stage-hr-her2-breast-cancer/ 2024-01-15T09:00:41+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1273858064.jpg https://www.fondazionebonadonna.eu/pemigatinib-nel-carcinoma-uroteliale-metastatico-o-non-operabile/ 2024-01-29T09:00:03+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_408276810_XL.jpg https://www.fondazionebonadonna.eu/dostarlimab-in-monoterapia-nei-tumori-solidi-con-deficit-di-riparazione-dei-mismatch/ 2024-01-22T09:00:17+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_297613181.jpg https://www.fondazionebonadonna.eu/en/dostarlimab-monotherapy-in-mismatch-repair-deficient-solid-tumors/ 2024-01-22T09:00:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_297613181.jpg https://www.fondazionebonadonna.eu/en/inavosilib-in-hr-her2-locally-advanced-or-metastatic-breast-cancer/ 2024-01-18T08:24:54+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_11045917_XL.jpg https://www.fondazionebonadonna.eu/en/pemigatinib-in-metastatic-or-surgically-unresectable-urothelial-carcinoma/ 2024-01-29T09:00:44+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_408276810_XL.jpg https://www.fondazionebonadonna.eu/atezolizumab-e-bevacizumab-nel-carcinoma-epatocellulare-ad-alto-rischio-dopo-resezione-o-ablazione/ 2024-02-05T09:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_46956221_XL.jpg https://www.fondazionebonadonna.eu/en/atezolizumab-and-bevacizumab-in-resected-or-ablated-high-risk-hepatocellular-carcinoma/ 2024-02-05T09:00:54+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_46956221_XL.jpg https://www.fondazionebonadonna.eu/due-giovani-ricercatrici-ottengono-ciascuna-una-borsa-di-studio-nellambito-della-terza-edizione-del-bando-in-memoria-di-gianni-bonadonna/ 2024-02-12T09:00:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/02/Immagine-per-News_12Feb24-scaled.jpg https://www.fondazionebonadonna.eu/en/two-young-researchers-awarded-with-two-fellowships-at-the-third-edition-of-the-call-in-memory-of-gianni-bonadonna/ 2024-02-12T09:00:05+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/02/Immagine-per-News_12Feb24-scaled.jpg https://www.fondazionebonadonna.eu/durvalumab-in-trattamento-perioperatorio-nel-tumore-del-polmone-non-a-piccole-cellule/ 2024-02-19T09:00:01+00:00 https://www.fondazionebonadonna.eu/en/perioperative-durvalumab-in-non-small-cell-lung-cancer/ 2024-02-19T09:00:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_102033612_XL.jpg https://www.fondazionebonadonna.eu/esiti-migliori-con-pembrolizumab-e-chemioterapia-nel-mesotelioma/ 2024-02-26T09:00:11+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_354727328_XL.jpg https://www.fondazionebonadonna.eu/en/improved-outcome-with-pembrolizumab-added-to-chemotherapy-in-mesothelioma/ 2024-02-26T09:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_354727328_XL.jpg https://www.fondazionebonadonna.eu/ladditivita-predice-lefficacia-delle-terapia-nei-tumori-avanzati/ 2024-03-04T09:00:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_340781962_XL.jpg https://www.fondazionebonadonna.eu/en/additivity-predicts-efficacy-of-therapies-for-advanced-cancer/ 2024-03-04T09:00:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_340781962_XL.jpg https://www.fondazionebonadonna.eu/en/ctdna-analysis-in-gastrointestinal-stromal-tumors-treated-with-ripretinib-or-sunitinib/ 2024-03-11T09:00:40+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-696241690.jpg https://www.fondazionebonadonna.eu/lanalisi-del-ctdna-in-tumori-stromali-gastrointestinali-trattati-con-ripretinib-o-sunitinib/ 2024-03-11T09:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-696241690.jpg https://www.fondazionebonadonna.eu/uno-studio-dimostra-per-la-prima-volta-la-sicurezza-della-combinazione-di-due-farmaci-anticorpo-coniugati/ 2024-03-18T09:00:33+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_75454042.jpeg https://www.fondazionebonadonna.eu/en/first-trial-showing-safety-of-a-combination-of-two-antibody-drug-conjugates/ 2024-03-18T09:00:58+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_75454042.jpeg https://www.fondazionebonadonna.eu/combinazioni-efficaci-di-farmaci-identificate-grazie-a-uno-screening-su-linee-cellulari-da-numerosi-tumori/ 2024-03-25T09:00:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/en/effective-drug-combinations-identified-by-pan-cancer-cell-line-screening/ 2024-03-25T09:00:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/i-cambiamenti-evolutivi-del-tumore-del-polmone-a-piccole-cellule-durante-la-terapia/ 2024-04-15T08:00:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_354727328_XL.jpg https://www.fondazionebonadonna.eu/en/the-evolutionary-changes-of-small-cell-lung-cancer-under-therapy/ 2024-04-15T08:00:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_354727328_XL.jpg https://www.fondazionebonadonna.eu/lefficacia-di-sunitinib-nei-feocromocitomi-e-paragangliomi-metastatici/ 2024-04-22T08:00:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_357876670_XL.jpg https://www.fondazionebonadonna.eu/en/efficacy-of-sunitinib-in-metastatic-phaeochromocytomas-and-paragangliomas/ 2024-04-22T08:00:00+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_357876670_XL.jpg https://www.fondazionebonadonna.eu/gli-effetti-di-pertuzumab-in-terapia-neoadiuvante-e-adiuvante-nel-tumore-mammario-her2-positivo-precoce/ 2024-04-08T08:00:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_217791222_XL.jpg https://www.fondazionebonadonna.eu/en/effects-of-neoadjuvant-adjuvant-pertuzumab-in-her2-positive-early-breast-cancer/ 2024-04-08T08:00:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_217791222_XL.jpg https://www.fondazionebonadonna.eu/un-nuovo-farmaco-testato-in-tumori-solidi-con-myc-come-bersaglio/ 2024-04-29T08:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/en/myc-targeting-with-a-new-agent-in-solid-tumors/ 2024-04-29T08:00:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/gli-effetti-dellaggiunta-di-palbociclib-e-avelumab-a-fulvestrant-nel-carcinoma-mammario-metastatico-hr-her2/ 2024-05-13T08:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_11045917_XL.jpg https://www.fondazionebonadonna.eu/en/effects-of-palbociclib-and-avelumab-added-to-fulvestrant-in-hr-her2-metastatic-breast-cancer/ 2024-05-13T08:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_11045917_XL.jpg https://www.fondazionebonadonna.eu/la-terapia-con-afamitresgene-autoleucel-nel-sarcoma-sinoviale-avanzato/ 2024-05-20T08:00:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/en/the-t-cell-receptor-therapy-with-afamitresgene-autoleucel-in-advanced-synovial-sarcoma/ 2024-05-20T08:00:14+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_325254602.jpeg https://www.fondazionebonadonna.eu/en/giredestrant-in-hr-her2-advanced-breast-cancer/ 2024-05-27T08:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_216414188_XL.jpg https://www.fondazionebonadonna.eu/giredestrant-nel-carcinoma-mammario-avanzato-hr-her2/ 2024-05-27T08:00:40+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_216414188_XL.jpg https://www.fondazionebonadonna.eu/en/the-autologous-t-cell-therapy-lifileucel-in-metastatic-non-small-cell-lung-cancer/ 2024-06-03T08:00:19+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_102033612_XL.jpg https://www.fondazionebonadonna.eu/la-terapia-autologa-con-cellule-t-lifileucel-nel-carcinoma-polmonare-non-a-piccole-cellule-metastatico/ 2024-06-03T08:00:49+00:00 https://www.fondazionebonadonna.eu/in-memoria-di-pinuccia-valagussa/ 2024-05-07T14:11:33+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/05/PV_Bn.jpg https://www.fondazionebonadonna.eu/en/in-memoriam-of-pinuccia-valagussa/ 2024-05-07T14:12:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/05/PV_Bn.jpg https://www.fondazionebonadonna.eu/la-de-escalation-della-chemioterapia-nel-tumore-mammario-precoce-her2/ 2024-06-10T08:00:23+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_217791222_XL.jpg https://www.fondazionebonadonna.eu/en/chemotherapy-de-escalation-in-her2-early-breast-cancer/ 2024-06-10T08:00:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_217791222_XL.jpg https://www.fondazionebonadonna.eu/en/a-new-call-for-applications-for-the-international-fellowship-in-honor-of-gianni-bonadonna/ 2024-06-07T08:00:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/al-via-il-nuovo-bando-per-borse-di-studio-allestero-intitolate-a-gianni-bonadonna/ 2024-06-07T08:00:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/lintelligenza-artificiale-nella-ricerca-oncologica-una-guida/ 2024-06-17T08:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_216470422.jpg https://www.fondazionebonadonna.eu/en/artificial-intelligence-in-cancer-research-a-guide/ 2024-06-17T08:00:48+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_216470422.jpg https://www.fondazionebonadonna.eu/unimmunoterapia-neoadiuvante-nel-carcinoma-al-colon-retto-avanzato/ 2024-06-24T08:00:01+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1256373514.jpg https://www.fondazionebonadonna.eu/en/neoadjuvant-immunotherapy-in-advanced-colon-cancer/ 2024-06-24T08:00:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1256373514.jpg https://www.fondazionebonadonna.eu/olaparib-con-e-senza-bevacizumab-nel-tumore-del-colon-retto-avanzato/ 2024-07-01T08:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1319439468.jpg https://www.fondazionebonadonna.eu/en/olaparib-with-or-without-bevacizumab-in-advanced-colorectal-cancer/ 2024-07-01T08:00:35+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1319439468.jpg https://www.fondazionebonadonna.eu/177lu-dotatate-e-ocreotide-come-terapia-di-prima-linea-nei-tumori-neuroendocrini/ 2024-07-08T10:46:03+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_180844752_XL.jpg https://www.fondazionebonadonna.eu/en/177lu-dotatate-plus-ocreotide-as-a-first-line-therapy-in-neuroendocrine-tumors/ 2024-07-08T10:47:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_180844752_XL.jpg https://www.fondazionebonadonna.eu/en/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer/ 2024-07-15T08:00:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_425875532_XL.jpg https://www.fondazionebonadonna.eu/il-serd-orale-camizestrant-nel-carcinoma-mammario-er-her2/ 2024-07-15T08:00:52+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_425875532_XL.jpg https://www.fondazionebonadonna.eu/un-farmaco-immuno-coniugato-mirato-a-her2-nel-carcinoma-mammario-metastatico/ 2024-07-22T08:00:06+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-839295568_2500.jpg https://www.fondazionebonadonna.eu/en/a-her2-targeting-antibody-drug-conjugate-in-metastatic-breast-cancer/ 2024-07-22T08:00:34+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-839295568_2500.jpg https://www.fondazionebonadonna.eu/tisotumab-vedotin-nel-tumore-della-cervice-uterina-recidivante/ 2024-07-29T08:00:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/07/Image_NEJM_29Jul24-scaled.jpg https://www.fondazionebonadonna.eu/en/tisotumab-vedotin-for-recurrent-cervical-cancer/ 2024-07-29T08:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/07/Image_NEJM_29Jul24-scaled.jpg https://www.fondazionebonadonna.eu/lefficacia-di-pembrolizumab-in-terapia-adiuvante-nel-carcinoma-a-cellule-renali/ 2024-08-05T08:00:41+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1167361072.jpg https://www.fondazionebonadonna.eu/en/efficacy-of-adjuvant-pembrolizumab-in-renal-cell-carcinoma/ 2024-08-05T08:00:28+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1167361072.jpg https://www.fondazionebonadonna.eu/luso-sequenziale-di-sacituzumab-govitecan-come-strategia-promettente-nel-tumore-mammario/ 2024-08-26T08:00:13+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1273858064.jpg https://www.fondazionebonadonna.eu/en/the-sequential-use-of-sacituzumab-govitecan-as-a-promising-strategy-in-breast-cancer/ 2024-08-26T08:00:23+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1273858064.jpg https://www.fondazionebonadonna.eu/lefficacia-di-osimertinib-nel-carcinoma-polmonare-non-a-piccole-cellule-con-mutazione-di-egfr/ 2024-09-02T08:00:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/omkh_436n_150824.jpg https://www.fondazionebonadonna.eu/en/efficacy-of-osimertinib-in-egfr-mutated-non-small-cell-lung-cancer/ 2024-09-02T08:00:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/omkh_436n_150824.jpg https://www.fondazionebonadonna.eu/quanti-studi-sullimmunoterapia-nel-tumore-mammario-si-traducono-in-trial-di-fase-iii-con-risultati-positivi/ 2024-09-09T08:00:03+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/09/Image_JamaNetwork_04Sep24-scaled.jpg https://www.fondazionebonadonna.eu/en/how-many-immunotherapy-trials-in-breast-cancer-translate-into-positive-phase-iii-trials/ 2024-09-09T08:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/09/Image_JamaNetwork_04Sep24-scaled.jpg https://www.fondazionebonadonna.eu/sicurezza-ed-efficacia-di-imlunestrant-nel-tumore-alla-mammella-avanzato-er-her2/ 2024-09-16T08:00:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_425875532_XL.jpg https://www.fondazionebonadonna.eu/en/safety-and-efficacy-of-imlunestrant-in-er-her2-advanced-breast-cancer/ 2024-09-16T08:00:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_425875532_XL.jpg https://www.fondazionebonadonna.eu/inavolisib-assieme-a-palbociclib-e-a-una-terapia-endocrina-nel-tumore-mammario-avanzato-er-her2/ 2024-09-23T08:00:25+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1356345613_2500.jpg https://www.fondazionebonadonna.eu/en/inavolisib-plus-palbociclib-and-endocrine-therapy-in-er-her2-advanced-breast-cancer/ 2024-09-23T08:00:24+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1356345613_2500.jpg https://www.fondazionebonadonna.eu/un-nuovo-biomarcatore-predittivo-dei-benefici-dellimmunoterapia-nel-tumore-mammario-triplo-negativo-validato-dal-neotrip-trial-2/ 2024-09-30T08:00:31+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/09/2024-06-DetermaIO-scaled.jpg https://www.fondazionebonadonna.eu/en/a-new-predictive-biomarker-of-immunotherapy-benefit-in-triple-negative-breast-cancer-was-validated-in-the-neotrip-trial-2/ 2024-09-30T08:00:14+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/09/2024-06-DetermaIO-scaled.jpg https://www.fondazionebonadonna.eu/laggiunta-di-trabectedina-a-doxorubicina-nel-leiomiosarcoma-avanzato/ 2024-10-07T08:00:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_239039608_XL.jpg https://www.fondazionebonadonna.eu/en/trabectedin-added-to-doxorubicin-in-advanced-leiomyosarcomalaggiunta-di-trabectedina-a-doxorubicina-nel-leiomiosarcoma-avanzato/ 2024-10-07T08:00:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_239039608_XL.jpg https://www.fondazionebonadonna.eu/atezolizumab-in-associazione-a-pertuzumab-e-trastuzumab-nel-tumore-mammario-metastatico-her2/ 2024-10-14T08:00:41+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_274592970_XL.jpg https://www.fondazionebonadonna.eu/en/atezolizumab-added-to-pertuzumab-plus-trastuzumab-in-her2-metastatic-breast-cancer/ 2024-10-14T08:00:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_274592970_XL.jpg https://www.fondazionebonadonna.eu/tocilizumab-nellartrite-associata-agli-inibitori-dei-checkpoint-immunitari/ 2024-10-21T08:00:57+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_340781962_XL.jpg https://www.fondazionebonadonna.eu/en/tocilizumab-in-immune-checkpoint-inhibitor-associated-arthritis/ 2024-10-21T08:00:10+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_340781962_XL.jpg https://www.fondazionebonadonna.eu/uno-screening-di-farmaci-neuroattivi-da-poter-utilizzare-nel-glioblastoma/ 2024-10-28T09:07:24+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/10/Image_Nature_28Oct24-scaled.jpg https://www.fondazionebonadonna.eu/en/a-screening-of-repurposable-neuroactive-drugs-in-glioblastoma/ 2024-10-28T09:00:48+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/10/Image_Nature_28Oct24-scaled.jpg https://www.fondazionebonadonna.eu/un-nuovo-breast-cancer-purity-score-basato-sullespressione-genica/ 2024-11-04T09:00:10+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/10/Image_Npj_04Nov24-scaled.jpg https://www.fondazionebonadonna.eu/en/a-new-gene-expression-based-breast-cancer-purity-score/ 2024-11-04T09:00:24+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/10/Image_Npj_04Nov24-scaled.jpg https://www.fondazionebonadonna.eu/una-biobanca-di-xenotrapianti-da-pazienti-con-tumore-mammario-per-studiare-leterogeneita-tumorale-e-i-meccanismi-di-resistenza/ 2024-11-11T09:00:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170950194_XL.jpg https://www.fondazionebonadonna.eu/una-risposta-duratura-con-pemigatinib-nel-colangiocarcinoma/ 2024-11-18T09:00:20+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/en/in-a-new-italian-study-a-comprehensive-luminal-breast-cancer-xenograft-library-to-capture-tumour-heterogeneity-and-explore-mechanisms-of-resistance-to-cdk4-6-inhibitors/ 2024-11-11T09:00:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170950194_XL.jpg https://www.fondazionebonadonna.eu/la-terapia-a-bersaglio-molecolare-in-aggiunta-a-un-anti-pd-l1-nel-carcinoma-anaplastico-della-tiroide/ 2024-12-02T09:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_259168782.jpg https://www.fondazionebonadonna.eu/en/durable-response-with-pemigatinib-in-cholangiocarcinoma/ 2024-11-18T09:00:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/risultati-positivi-con-inavosilib-combinato-a-palbociclib-e-fulvestrant-nel-carcinoma-mammario-avanzato/ 2024-11-25T09:00:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/11/Image_nejm_25Nov24-scaled.jpg https://www.fondazionebonadonna.eu/en/positive-results-with-inavosilib-added-to-palbociclib-and-fulvestrant-in-advanced-breast-cancer/ 2024-11-25T09:00:50+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/11/Image_nejm_25Nov24-scaled.jpg https://www.fondazionebonadonna.eu/en/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma/ 2024-12-02T09:00:17+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_259168782.jpg https://www.fondazionebonadonna.eu/camizestrant-a-confronto-con-fulvestrant-nel-tumore-mammario-avanzato-in-post-menopausa/ 2024-12-09T09:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/12/Image_lancet_09Dec24-1-scaled.jpg https://www.fondazionebonadonna.eu/en/camizestrant-versus-fulvestrant-in-postmenopausal-advanced-breast-cancer/ 2024-12-09T09:00:59+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2024/12/Image_lancet_09Dec24-1-scaled.jpg https://www.fondazionebonadonna.eu/efficacia-della-terapia-neoadiuvante-con-nivolumab-relatlimab-nel-tumore-del-colon-localmente-avanzato/ 2024-12-16T09:00:33+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_66830781-scaled.jpeg https://www.fondazionebonadonna.eu/paclitaxel-e-ramucirumab-nel-tumore-gastrico-avanzato-o-nel-tumore-della-giunzione-gastro-esofagea/ 2024-12-23T09:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1332513809.jpg https://www.fondazionebonadonna.eu/en/efficacy-of-neoadjuvant-nivolumab-relatlimab-in-locally-advanced-colon-cancer/ 2024-12-16T09:00:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_66830781-scaled.jpeg https://www.fondazionebonadonna.eu/en/paclitaxel-and-ramucirumab-in-advanced-gastric-or-gastro-esophageal-junction-cancer/ 2024-12-23T09:00:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/03/iStock-1332513809.jpg https://www.fondazionebonadonna.eu/fianlimab-e-cemiplimab-in-pazienti-con-tumori-avanzati/ 2025-01-13T09:00:41+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/01/Image_aacr_13Jan25-scaled.jpg https://www.fondazionebonadonna.eu/en/fianlimab-and-cemiplimab-in-patients-with-advanced-tumors/ 2025-01-13T09:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/01/Image_aacr_13Jan25-scaled.jpg https://www.fondazionebonadonna.eu/nivolumab-e-ipilimumab-in-terapia-neoadiuvante-nel-carcinoma-polmonare-resecabile/ 2025-01-20T09:00:50+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_21053222.jpg https://www.fondazionebonadonna.eu/en/neoadjuvant-nivolumab-plus-ipilimumab-in-resectable-lung-cancer/ 2025-01-20T09:00:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/10/AdobeStock_21053222.jpg https://www.fondazionebonadonna.eu/lenvatinib-e-pembrolizumab-in-aggiunta-allembolizzazione-transarteriosa-nel-carcinoma-epatocellulare/ 2025-01-27T09:00:19+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/01/Image_lancet_27Jan25-scaled.jpg https://www.fondazionebonadonna.eu/en/lenvatinib-plus-pembrolizumab-added-to-transarterial-embolization-in-hepatocellular-carcinoma/ 2025-01-27T09:00:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/01/Image_lancet_27Jan25-scaled.jpg https://www.fondazionebonadonna.eu/talquetamab-e-teclistamab-nel-mieloma-multiplo/ 2025-02-10T09:00:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_276496579.jpeg https://www.fondazionebonadonna.eu/en/talquetamab-plus-teclistamab-in-multiple-myeloma/ 2025-02-10T09:00:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/AdobeStock_276496579.jpeg https://www.fondazionebonadonna.eu/la-quarta-edizione-della-borsa-di-studio-intitolata-a-gianni-bonadonna-premia-tre-giovani-ricercatori/ 2025-02-04T16:33:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/en/the-fourth-edition-of-the-fellowship-named-after-gianni-bonadonna-awards-three-young-researchers/ 2025-02-04T16:40:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/tucatinib-e-trastuzumab-nel-tumore-mammario-metastatico-con-mutazione-di-her2/ 2025-02-17T09:00:15+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_11045917_XL.jpg https://www.fondazionebonadonna.eu/en/tucatinib-and-trastuzumab-in-her2-mutated-metastatic-breast-cancer/ 2025-02-17T09:00:05+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_11045917_XL.jpg https://www.fondazionebonadonna.eu/encorafenib-cetuximab-e-chemioterapia-nel-carcinoma-colorettale-metastatico/ 2025-02-24T09:00:33+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/02/Image_Nature_24Feb25-scaled.jpg https://www.fondazionebonadonna.eu/en/encorafenib-cetuximab-and-chemotherapy-in-metastatic-colorectal-cancer/ 2025-02-24T15:06:10+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/02/Image_Nature_24Feb25-scaled.jpg https://www.fondazionebonadonna.eu/en/nivolumab-and-ipilimumab-in-metastatic-colorectal-cancer/ 2025-03-03T10:30:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/03/Image_lancet_03Mar25-1-scaled.jpg https://www.fondazionebonadonna.eu/nivolumab-e-ipilimumab-nel-carcinoma-del-colon-retto-metastatico/ 2025-03-03T10:30:39+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/03/Image_lancet_03Mar25-1-scaled.jpg https://www.fondazionebonadonna.eu/nuove-indicazioni-sui-driver-e-le-dinamiche-della-risposta-alle-terapie-target-nel-tumore-mammario-her-er/ 2025-03-10T09:00:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/03/Image_Nature_10Mar25-scaled.jpg https://www.fondazionebonadonna.eu/en/new-insights-into-the-drivers-and-dynamics-of-her2-er-breast-cancer-response-to-targeted-treatments/ 2025-03-10T09:00:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/03/Image_Nature_10Mar25-scaled.jpg https://www.fondazionebonadonna.eu/ibrutinib-e-venetoclax-nel-linfoma-mantellare-refrattario/ 2025-03-17T14:41:29+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1138937146.jpg https://www.fondazionebonadonna.eu/en/ibrutinib-plus-venetoclax-in-refractory-mantle-cell-lymphoma/ 2025-03-17T14:47:02+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1138937146.jpg https://www.fondazionebonadonna.eu/tiragolumab-con-atezolizumab-e-bevacizumab-nel-carcinoma-epatocellulare-non-resecabile/ 2025-03-24T09:00:40+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/03/Image_lancet_24Mar25-scaled.jpg https://www.fondazionebonadonna.eu/en/tiragolumab-with-atezolizumab-and-bevacizumab-in-unresectable-hepatocellular-carcino-ma/ 2025-03-24T09:01:40+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/03/Image_lancet_24Mar25-scaled.jpg https://www.fondazionebonadonna.eu/ivonescimab-a-confronto-con-pembrolizumab-nel-carcinoma-polmonare-non-a-piccole-cellule-positivo-a-pd-l1/ 2025-03-31T08:00:20+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/03/Image_lancet_31Mar25-scaled.jpg https://www.fondazionebonadonna.eu/la-validazione-del-biomarcatore-oracle-nelladenocarcinoma-polmonare/ 2025-04-07T08:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_354727328_XL.jpg https://www.fondazionebonadonna.eu/en/ivonescimab-versus-pembrolizumab-in-pd-l1-positive-non-small-cell-lung-cancer/ 2025-03-31T08:06:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/03/Image_lancet_31Mar25-scaled.jpg https://www.fondazionebonadonna.eu/en/the-validation-of-the-oracle-biomarker-in-lung-adenocarcinoma/ 2025-04-07T08:00:05+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_354727328_XL.jpg https://www.fondazionebonadonna.eu/en/dna-methylation-landscape-of-primary-triple-negative-breast-cancer/ 2025-04-14T08:00:23+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/04/Image_Nature_28Apr25-scaled.jpg https://www.fondazionebonadonna.eu/profili-di-metilazione-del-dna-nel-carcinoma-mammario-triplo-negativo/ 2025-04-14T08:00:31+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/04/Image_Nature_28Apr25-scaled.jpg https://www.fondazionebonadonna.eu/avelumab-e-axitinib-a-confronto-con-suritinib-come-terapia-di-prima-linea-nel-carcinoma-a-cellule-renali-avanzato/ 2025-04-28T08:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/04/Image_AnnalsOncology_28Apr25-scaled.jpg https://www.fondazionebonadonna.eu/en/avelumab-plus-axitinib-versus-sunitinib-as-first-line-treatment-in-advanced-renal-cell-carcinoma/ 2025-04-28T08:00:24+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/04/Image_AnnalsOncology_28Apr25-scaled.jpg https://www.fondazionebonadonna.eu/regorafenib-e-avelumab-nei-tumori-neuroendocrini-gastroenteropancreatici/ 2025-05-05T08:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/05/Image_Nature_05May25-scaled.jpg https://www.fondazionebonadonna.eu/en/regorafenib-plus-avelumab-in-gastroenteropancreatic-neuroendocrine-neoplasms/ 2025-05-05T10:06:44+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/05/Image_Nature_05May25-scaled.jpg https://www.fondazionebonadonna.eu/sacituzumab-tirumotecan-nel-carcinoma-mammario-triplo-negativo-metastatico/ 2025-05-12T08:00:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/05/Image_Nature_12May25-scaled.jpg https://www.fondazionebonadonna.eu/en/sacituzumab-tirumotecan-in-metastatic-triple-negative-breast-cancer/ 2025-05-12T08:20:14+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/05/Image_Nature_12May25-scaled.jpg https://www.fondazionebonadonna.eu/durvalumab-con-o-senza-trepelimumab-in-combinazione-alla-chemioterapia-nel-carcinoma-polmonare-non-a-piccole-cellule-metastatico/ 2025-06-16T08:00:03+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_30135963_XL.jpg https://www.fondazionebonadonna.eu/afamitresgene-autoleucel-nel-sarcoma-sinoviale-e-nel-liposarcoma-a-cellule-moxoidi-avanzati/ 2025-05-19T10:00:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/05/Image_Lancet_19May25-scaled.jpg https://www.fondazionebonadonna.eu/en/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma/ 2025-05-19T10:00:33+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/05/Image_Lancet_19May25-scaled.jpg https://www.fondazionebonadonna.eu/trastuzumab-rezetecan-nel-carcinoma-polmonare-non-a-piccole-cellule-avanzato-con-mutazione-di-her2/ 2025-06-09T08:00:29+00:00 https://www.fondazionebonadonna.eu/en/a-new-edition-for-the-international-fellowships-in-honor-of-gianni-bonadonna/ 2025-05-26T08:07:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/in-partenza-la-nuova-edizione-delle-borse-di-studio-allestero-intitolate-a-gianni-bonadonna/ 2025-05-26T08:08:05+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/nivolumab-in-associazione-a-ipilimumab-a-basso-dosaggio-nel-carcinoma-mammario-metastatico-her2-negativo/ 2025-06-30T08:00:10+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1138405349.jpg https://www.fondazionebonadonna.eu/en/trastuzumab-rezetecan-in-advanced-her2-mutant-non-small-cell-lung-cancer/ 2025-06-09T08:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_102033612_XL.jpg https://www.fondazionebonadonna.eu/en/durvalumab-with-or-without-tremelimumab-in-combination-with-chemotherapy-in-first-line-metastatic-non-small-cell-lung-cancer/ 2025-06-16T08:00:58+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_30135963_XL.jpg https://www.fondazionebonadonna.eu/en/neoadjuvant-trastuzumab-rezetecan-in-her2-positive-breast-cancer/ 2025-06-23T08:00:25+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/06/Image_AnnalsOncology_23Jun25-scaled.jpg https://www.fondazionebonadonna.eu/trastuzumab-rezetecan-in-terapia-neoadiuvante-nel-carcinoma-mammario-her2/ 2025-06-23T08:00:03+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/06/Image_AnnalsOncology_23Jun25-scaled.jpg https://www.fondazionebonadonna.eu/en/nivolumab-and-low-dose-ipilimumab-in-her2-negative-metastatic-breast-cancer/ 2025-06-30T08:00:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1138405349.jpg https://www.fondazionebonadonna.eu/en/alectinib-plus-bevacizumab-in-alk-rearranged-non-small-cell-lung-cancer/ 2025-07-07T08:00:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/48100511.jpg https://www.fondazionebonadonna.eu/alectinib-in-combinazione-con-bevacizumab-nel-carcinoma-polmonare-non-a-piccole-cellule-con-riarrangiamenti-di-alk/ 2025-07-07T08:00:35+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/48100511.jpg https://www.fondazionebonadonna.eu/pembrolizumab-aggiunto-a-ezalutamide-e-alla-terapia-di-deprivazione-androgenica-nel-carcinoma-prostatico-metastatico/ 2025-07-21T08:00:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_66084201_XL.jpg https://www.fondazionebonadonna.eu/inavosilib-nel-carcinoma-mammario-avanzato-con-mutazioni-in-pik3ca/ 2025-07-14T08:00:06+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/07/Image_nejm_14Jul25-scaled.jpg https://www.fondazionebonadonna.eu/en/inavosilib-in-pik3ca-mutated-advanced-breast-cancer/ 2025-07-14T08:00:12+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/07/Image_nejm_14Jul25-scaled.jpg https://www.fondazionebonadonna.eu/cemiplimab-nel-carcinoma-cutaneo-squamocellulare-ad-alto-rischio/ 2025-07-28T08:00:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/07/Image_nejm_28Jul25-scaled.jpg https://www.fondazionebonadonna.eu/en/cemiplimab-in-high-risk-cutaneous-squamous-cell-carcinoma/ 2025-07-28T08:00:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/07/Image_nejm_28Jul25-scaled.jpg https://www.fondazionebonadonna.eu/en/pembrolizumab-plus-enzalutamide-and-androgen-deprivation-therapy-in-prostate-cancer/ 2025-07-21T10:19:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_66084201_XL.jpg https://www.fondazionebonadonna.eu/trastuzumab-deruxtecan-o-ramucirumab-in-combinazione-con-paclitaxel-nel-carcinoma-gastrico/ 2025-08-04T08:00:46+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/07/Image_nejm_04Aug25-scaled.jpg https://www.fondazionebonadonna.eu/una-maggiore-sopravvivenza-con-tarlatamab-nel-carcinoma-polmonare-a-piccole-cellule/ 2025-08-25T08:00:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/08/Image_nejm_25Aug25-scaled.jpg https://www.fondazionebonadonna.eu/en/longer-survival-with-tarlatamab-in-small-cell-lung-cancer/ 2025-08-25T08:00:01+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/08/Image_nejm_25Aug25-scaled.jpg https://www.fondazionebonadonna.eu/la-combinazione-di-pirotinib-e-un-farmaco-immuno-coniugato-nel-carcinoma-mammario-her2/ 2025-09-15T08:00:44+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_274592970_XL.jpg https://www.fondazionebonadonna.eu/en/trastuzumab-deruxtecan-or-ramucirumab-plus-paclitaxel-in-gastric-cancer/ 2025-08-04T08:04:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/07/Image_nejm_04Aug25-scaled.jpg https://www.fondazionebonadonna.eu/la-terapia-peri-operatoria-con-durvalumab-nel-carcinoma-gastrico-e-della-giunzione-gastroesofagea/ 2025-09-01T08:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/09/Image_nejm_01Sep25-scaled.jpg https://www.fondazionebonadonna.eu/en/perioperative-durvalumab-in-gastric-and-gastroesophageal-junction-cancer/ 2025-09-01T08:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/09/Image_nejm_01Sep25-scaled.jpg https://www.fondazionebonadonna.eu/camizestrant-in-prima-linea-nel-carcinoma-mammario-avanzato-mutato-in-esr-1/ 2025-09-08T08:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/09/Image_nejm_08Sep25-scaled.jpg https://www.fondazionebonadonna.eu/en/first-line-camizestrant-for-esr-1-mutated-advanced-breast-cancer/ 2025-09-08T08:00:19+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/09/Image_nejm_08Sep25-scaled.jpg https://www.fondazionebonadonna.eu/en/pyrotinib-plus-a-new-antibody-drug-conjugate-in-her-breast-cancer/ 2025-09-15T08:00:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_274592970_XL.jpg https://www.fondazionebonadonna.eu/atezolizumab-paclitaxel-e-bevacizumab-in-terapia-di-prima-linea-nel-carcinoma-mammario-triplo-negativo/ 2025-09-22T08:00:20+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/09/Image_Nature_22Sep25-scaled.jpg https://www.fondazionebonadonna.eu/en/atezolizumab-paclitaxel-and-bevacizumab-as-first-line-therapy-in-triple-negative-breast-cancer/ 2025-09-22T08:01:52+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/09/Image_Nature_22Sep25-scaled.jpg https://www.fondazionebonadonna.eu/camizestrant-in-associazione-a-tre-inibitori-di-cdk4-6-nel-carcinoma-mammario-avanzato/ 2025-10-06T08:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/10/Image_aacr_06Oct25-scaled.jpg https://www.fondazionebonadonna.eu/cellule-metastatiche-di-carcinoma-mammario-possono-essere-risvegliate-da-infezioni-polmonari/ 2025-09-30T08:16:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/09/Image_Nature_29Sep25-scaled.jpg https://www.fondazionebonadonna.eu/en/metastatic-breast-cancer-cells-awakened-by-lung-infections/ 2025-09-30T08:17:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/09/Image_Nature_29Sep25-scaled.jpg https://www.fondazionebonadonna.eu/en/camizestrant-with-three-cdk4-6-inhibitors-in-advanced-breast-cancer/ 2025-10-06T08:01:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/10/Image_aacr_06Oct25-scaled.jpg https://www.fondazionebonadonna.eu/il-farmaco-immuno-coniugato-precemtabart-tocentecan-nel-carcinoma-colorettale-metastatico/ 2025-10-13T08:00:04+00:00 https://www.fondazionebonadonna.eu/en/the-antibody-drug-conjugate-precemtabart-tocentecan-in-metastatic-colorectal-cancer/ 2025-10-13T08:05:57+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_73644269_XL.jpg https://www.fondazionebonadonna.eu/patritumab-deruxtecan-nel-carcinoma-mammario-avanzato-hr-her2/ 2025-10-20T08:00:25+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/10/Image_Nature_20Oct25-scaled.jpg https://www.fondazionebonadonna.eu/en/patritumab-deruxtecan-in-hr-her2-advanced-breast-cancer/ 2025-10-20T08:39:06+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/10/Image_Nature_20Oct25-scaled.jpg https://www.fondazionebonadonna.eu/pembrolizumab-e-radioterapia-nel-carcinoma-polmonare-non-a-piccole-cellule-immunologicamente-freddo/ 2025-10-27T09:05:08+00:00 https://www.fondazionebonadonna.eu/en/pembrolizumab-and-radiotherapy-in-immunologically-cold-non-small-cell-lung-cancer/ 2025-10-27T09:05:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_102033612_XL.jpg https://www.fondazionebonadonna.eu/capivasertib-e-abiraterone-nel-carcinoma-prostatico-metastatico-ormono-sensibile/ 2025-11-03T09:00:10+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/11/Image_AnnalsOncology_03Nov25-scaled.jpg https://www.fondazionebonadonna.eu/en/capivasertib-plus-abiraterone-in-metastatic-hormone-sensitive-prostate-cancer/ 2025-11-03T09:02:58+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/11/Image_AnnalsOncology_03Nov25-scaled.jpg https://www.fondazionebonadonna.eu/i-vaccini-per-sars-cov-2-sensibilizzano-i-tumori-al-blocco-con-inibitori-dei-checkpoint-immunitari/ 2025-11-10T09:32:40+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/en/sars-cov-2-vaccines-sensitize-tumors-to-immune-checkpoint-blockade/ 2025-11-10T09:33:01+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/dai-nuovi-farmaci-allintelligenza-artificiale-le-novita-in-oncologia/ 2025-11-17T13:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/11/JC_Image_17Nov25_HP-scaled.jpg https://www.fondazionebonadonna.eu/en/from-new-drugs-to-artificial-intelligence-the-news-in-oncology/ 2025-11-17T13:00:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/11/JC_Image_17Nov25_HP-scaled.jpg https://www.fondazionebonadonna.eu/la-rilevanza-del-microambiente-tumorale-per-gli-esiti-clinici-nel-tumore-della-mammella/ 2025-11-24T09:00:01+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/11/Image_24Nov25-scaled.jpg https://www.fondazionebonadonna.eu/en/the-relevance-of-tumor-microenvironment-for-clinical-outcomes-in-breast-cancer/ 2025-11-24T09:03:57+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/11/Image_24Nov25-scaled.jpg https://www.fondazionebonadonna.eu/lattivita-di-patritumab-deruxtrecan-in-pazienti-con-carcinoma-mammario-e-metastasi-cerebrali/ 2025-12-01T09:00:00+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/12/Image_Lancet_01Dec25-scaled.jpg https://www.fondazionebonadonna.eu/en/patritumab-deruxtecan-activity-in-breast-cancer-patients-with-brain-metastases/ 2025-12-01T09:02:57+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/12/Image_Lancet_01Dec25-scaled.jpg https://www.fondazionebonadonna.eu/pembrolizumab-in-terapia-neoadiuvante-e-adiuvante-in-un-tumore-testa-collo/ 2025-12-15T09:00:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/12/Image_nejm_12Dec25-scaled.jpg https://www.fondazionebonadonna.eu/en/neoadjuvant-and-adjuvant-pembrolizumab-in-head-and-neck-cancer/ 2025-12-15T09:03:19+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/12/Image_nejm_12Dec25-scaled.jpg https://www.fondazionebonadonna.eu/nel-carcinoma-mammario-la-sopravvivenza-libera-da-malattia-migliora-con-giredestrant-in-terapia-adiuvante/ 2025-12-23T08:15:59+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_274592970_XL.jpg https://www.fondazionebonadonna.eu/una-terapia-con-atezolizumab-guidata-dal-monitoraggio-del-ctdna-nel-tumore-della-vescica/ 2025-12-29T09:00:15+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/12/Image_nejm_29Dec25-scaled.jpg https://www.fondazionebonadonna.eu/cellule-car7-t-universali-ottenute-con-editing-di-una-base-nella-leucemia-linfoblastica-acuta/ 2026-01-19T09:00:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_164594362_XL.jpg https://www.fondazionebonadonna.eu/en/disease-free-survival-improvement-with-adjuvant-giredestrant-in-breast-cancer/ 2025-12-29T08:32:45+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_274592970_XL.jpg https://www.fondazionebonadonna.eu/en/a-ctdna-guided-atezolizumab-therapy-in-bladder-cancer/ 2025-12-29T09:01:24+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2025/12/Image_nejm_29Dec25-scaled.jpg https://www.fondazionebonadonna.eu/sacituzumab-govitecan-nel-carcinoma-mammario-avanzato-triplo-negativo/ 2026-01-12T09:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/01/Image_nejm_12Jan26-scaled.jpg https://www.fondazionebonadonna.eu/en/sacituzumab-govitecan-in-advanced-triple-negative-breast-cancer/ 2026-01-12T09:00:58+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/01/Image_nejm_12Jan26-scaled.jpg https://www.fondazionebonadonna.eu/lefficacia-di-patritumab-deruxtecan-sulle-metastasi-cerebrali-in-pazienti-con-carcinoma-polmonare-non-a-piccole-cellule/ 2026-02-09T09:00:46+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_30135963_XL.jpg https://www.fondazionebonadonna.eu/en/universal-base-edited-car7-t-cells-in-acute-lymphoblastic-leukemia/ 2026-01-19T09:02:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/06/Depositphotos_164594362_XL.jpg https://www.fondazionebonadonna.eu/tre-anziche-sei-mesi-di-chemioterapia-adiuvante-nel-tumore-del-colon-retto/ 2026-01-26T09:00:44+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/01/Image_ascopubs_26Jan26-scaled.jpg https://www.fondazionebonadonna.eu/en/three-versus-six-months-of-adjuvant-chemotherapy-in-colorectal-cancer/ 2026-01-26T09:00:23+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/01/Image_ascopubs_26Jan26-scaled.jpg https://www.fondazionebonadonna.eu/en/premiati-tre-giovani-ricercatori-nella-quinta-edizione-della-borsa-di-studio-intitolata-a-gianni-bonadonna/ 2026-02-04T08:40:57+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2021/04/cropped-fgb_512.jpg https://www.fondazionebonadonna.eu/premiati-tre-giovani-ricercatori-nella-quinta-edizione-della-borsa-di-studio-intitolata-a-gianni-bonadonna/ 2026-02-04T08:41:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/en/efficacy-of-patritumab-deruxtecan-on-brain-metastases-in-non-small-cell-lung-cancer-carcinoma/ 2026-02-09T09:01:06+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_30135963_XL.jpg https://www.fondazionebonadonna.eu/una-combinazione-di-nivolumab-e-ipilimumab-nei-carcinomi-non-colorettali/ 2026-02-16T09:00:15+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/camrelizumab-e-chemioterapia-in-terapia-neoadiuvante-nel-carcinoma-esofageo-a-cellule-squamose-resecabile/ 2026-02-23T09:00:18+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_12823119_XL.jpg https://www.fondazionebonadonna.eu/camrelizumab-in-aggiunta-alla-chemioterapia-neoadiuvante-nel-carcinoma-mammario-triplo-negativo/ 2026-03-02T09:00:07+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_425875532_XL.jpg https://www.fondazionebonadonna.eu/en/a-combination-of-nivolumab-and-ipilimumab-in-noncolorectal-cancers/ 2026-02-16T09:00:51+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_102728682_XL.jpg https://www.fondazionebonadonna.eu/en/camrelizumab-plus-chemotherapy-as-neoadjuvant-therapy-in-resectable-esophageal-squamous-cell-carcinoma/ 2026-02-23T09:01:31+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_12823119_XL.jpg https://www.fondazionebonadonna.eu/immunocitochine-mirate-in-terapia-neoadiuvante-nel-melanoma/ 2026-03-09T09:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/03/Image_AnnalsOncology_09Mar26-scaled.jpg https://www.fondazionebonadonna.eu/en/targeted-immunocytokines-as-a-neoadjuvant-treatment-in-melanoma/ 2026-03-09T09:00:40+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/03/Image_AnnalsOncology_09Mar26-scaled.jpg https://www.fondazionebonadonna.eu/en/neoadjuvant-camrelizumab-plus-chemotherapy-in-triple-negative-breast-cancer/ 2026-03-02T09:01:26+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_425875532_XL.jpg https://www.fondazionebonadonna.eu/anbenitamab-nel-carcinoma-gastrico-her2-positivo-gia-trattato/ 2026-03-16T09:00:14+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/03/Image_AnnalsOncology_16Mar26-scaled.jpg https://www.fondazionebonadonna.eu/en/anbenitamab-in-previously-treated-her2-positive-gastric-cancer/ 2026-03-16T09:00:15+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/03/Image_AnnalsOncology_16Mar26-scaled.jpg https://www.fondazionebonadonna.eu/ipilimumab-in-associazione-anivolumab-in-terapia-neoadiuvante-nel-melanoma/ 2026-03-23T13:07:58+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_261932205.jpg https://www.fondazionebonadonna.eu/en/neoadjuvant-ipilimumab-plus-nivolumab-in-melanoma/ 2026-03-23T13:08:36+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/01/AdobeStock_261932205.jpg https://www.fondazionebonadonna.eu/en/palbociclib-added-to-anti-her2-and-endocrine-therapies-in-advanced-breast-cancer-results-from-the-patina-study/ 2026-03-30T08:00:21+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/03/Image_nejm_24Mar26-scaled.jpg https://www.fondazionebonadonna.eu/palbociclib-in-aggiunta-alle-terapie-endocrine-e-anti-her2-nel-carcinoma-mammario-avanzato-i-risultati-dello-studio-patina/ 2026-03-30T08:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/03/Image_nejm_24Mar26-scaled.jpg https://www.fondazionebonadonna.eu/un-confronto-fra-mfolfrinox-e-paxg-nelladenocarcinoma-duttale-del-pancreas/ 2026-04-13T08:00:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/04/Image_Lancet_13Apr26-scaled.jpg https://www.fondazionebonadonna.eu/en/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma/ 2026-04-13T08:00:28+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/04/Image_Lancet_13Apr26-scaled.jpg https://www.fondazionebonadonna.eu/zanidatamab-nel-carcinoma-delle-vie-biliari-metastatico-e-positivo-a-her2/ 2026-04-20T08:00:41+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/04/Image_Jama_20Apr26-scaled.jpg https://www.fondazionebonadonna.eu/en/zanidatamab-in-her2-positive-metastatic-biliary-tract-cancer/ 2026-04-20T08:00:17+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/04/Image_Jama_20Apr26-scaled.jpg https://www.fondazionebonadonna.eu/en/the-use-of-intratumoral-radioenhancer-nanoparticle-nbtxr3-in-head-and-neck-cancer/ 2026-04-27T08:00:11+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_192455350_XL.jpg https://www.fondazionebonadonna.eu/liniezione-intratumorale-della-nanoparticella-radio-sensibilizzante-nbtxr3-nei-carcinomi-di-testa-e-collo/ 2026-04-27T08:00:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2023/09/Depositphotos_192455350_XL.jpg https://www.fondazionebonadonna.eu/il-trapianto-di-microbiota-fecale-insieme-allimmunoterapia-nel-carcinoma-polmonare-non-a-piccole-cellule-e-nel-melanoma/ 2026-05-04T08:00:56+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/05/Image_Nature_04May26-scaled.jpg https://www.fondazionebonadonna.eu/en/fecal-microbiota-transplantation-plus-immunotherapy-in-non-small-cell-lung-cancer-and-melanoma/ 2026-05-04T08:00:05+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/05/Image_Nature_04May26-scaled.jpg https://www.fondazionebonadonna.eu/en/a-new-edition-for-the-international-fellowships-in-honor-of-gianni-bonadonna-2/ 2026-05-11T08:00:52+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/al-via-la-nuova-edizione-per-le-borse-di-studio-allestero-intitolate-a-gianni-bonadonna/ 2026-05-11T08:00:06+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/la-risomministrazione-di-un-inibitore-parp-piu-bevacizumab-nel-carcinoma-ovarico/ 2026-05-18T08:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/05/Image_aacr_18May26-scaled.jpg https://www.fondazionebonadonna.eu/en/parp-inhibitor-rechallenge-plus-bevacizumab-in-ovarian-cancer/ 2026-05-18T08:00:55+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/05/Image_aacr_18May26-scaled.jpg https://www.fondazionebonadonna.eu/lattivita-di-tucatinib-e-trastuzumab-nel-tumore-del-colon-retto-metastatico-refrattario-alla-chemioterapia/ 2026-05-25T08:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/05/Image_Nature_25May26-scaled.jpg https://www.fondazionebonadonna.eu/en/tucatinib-plus-trastuzumab-in-chemotherapy-refractory-metastatic-colorectal-cancer/ 2026-05-25T08:00:30+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/05/Image_Nature_25May26-scaled.jpg https://www.fondazionebonadonna.eu/la-borsa-di-studio-intitolata-a-gianni-bonadonna-nel-racconto-di-chi-lha-vissuta/ 2026-06-08T08:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/en/the-fellowship-in-honor-of-gianni-bonadonna-coming-back-for-the-2026-edition-in-the-words-of-researchers-who-lived-it/ 2026-06-08T08:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/02/Senza-titolo-1.jpg https://www.fondazionebonadonna.eu/lefficacia-dellimmunoterapia-a-bassissimo-dosaggio-in-tumori-solidi-recidivanti-e-refrattari/ 2026-06-15T08:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1167361072.jpg https://www.fondazionebonadonna.eu/en/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors/ 2026-06-15T08:00:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/11/iStock-1167361072.jpg https://www.fondazionebonadonna.eu/cabozantinib-e-temozolomide-nei-sarcomi-dei-tessuti-molli-non-operabili-o-metastatici/ 2026-06-29T08:00:29+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/limmunoterapia-neoadiuvante-prima-della-chemio-radioterapia-nel-carcinoma-squamoso-della-cervice-uterina/ 2026-06-22T08:00:38+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/06/Image_Nature_22Jun26-scaled.jpg https://www.fondazionebonadonna.eu/en/neoadjuvant-immunotherapy-before-chemoradiation-in-cervical-squamous-carcinoma/ 2026-06-22T08:00:32+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/06/Image_Nature_22Jun26-scaled.jpg https://www.fondazionebonadonna.eu/en/cabozantinib-and-temozolomide-in-unresectable-or-metastatic-soft-tissue-sarcomas/ 2026-06-29T08:00:53+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2022/12/Depositphotos_170941728_XL.jpg https://www.fondazionebonadonna.eu/en/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors/ 2026-07-06T08:00:28+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/07/Image_Nature_06Jul26-scaled.jpg https://www.fondazionebonadonna.eu/repotrectinib-in-tumori-solidi-avanzati-positivi-per-fusioni-di-ntrk/ 2026-07-06T08:00:49+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/07/Image_Nature_06Jul26-scaled.jpg https://www.fondazionebonadonna.eu/la-terapia-adiuvante-con-nivolumab-e-relatlimab-nel-melanoma-di-stadio-iii-iv/ 2026-07-14T08:00:08+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/07/Image_Nature_13Jul26-scaled.jpg https://www.fondazionebonadonna.eu/en/adjuvant-nivolumab-plus-relatlimab-in-stage-iii-iv-melanoma/ 2026-07-14T08:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/07/Image_Nature_13Jul26-scaled.jpg https://www.fondazionebonadonna.eu/sacituzumab-govitecan-in-associazione-a-pembrolizumab-nel-carcinoma-mammario-triplo-negativo/ 2026-07-20T08:00:16+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/07/TNBC_20July26.jpg https://www.fondazionebonadonna.eu/en/sacituzumab-govitecan-plus-pembrolizumab-in-triple-negative-breast-cancer/ 2026-07-20T08:00:47+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/07/TNBC_20July26.jpg https://www.fondazionebonadonna.eu/una-nuova-strategia-pre-trapianto-di-successo-senza-chemio-o-radioterapia/ 2026-07-27T08:00:04+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/07/Image_Nature_27Jul26-scaled.jpg https://www.fondazionebonadonna.eu/en/a-new-successful-pre-transplant-strategy-without-chemo-or-radiotherapy/ 2026-07-27T08:00:37+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/07/Image_Nature_27Jul26-scaled.jpg https://www.fondazionebonadonna.eu/nivolumab-in-combinazione-con-ipilimumab-come-terapia-di-prima-linea-nel-carcinoma-a-cellule-renali-avanzato/ 2026-08-03T08:00:09+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/08/Image_AnnalsOncology_03Aug26-scaled.jpg https://www.fondazionebonadonna.eu/en/nivolumab-plus-ipilimumab-as-first-line-therapy-of-advanced-renal-cell-carcinoma/ 2026-08-03T08:00:42+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/08/Image_AnnalsOncology_03Aug26-scaled.jpg https://www.fondazionebonadonna.eu/pembrolizumab-e-paclitaxel-nel-carcinoma-ovarico-recidivante-e-resistente-alle-terapie-a-base-di-platino/ 2026-08-24T08:00:59+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/08/Image_Lancet_24Aug26-scaled.jpg https://www.fondazionebonadonna.eu/en/pembrolizumab-plus-weekly-paclitaxel-in-platinum-resistant-recurrent-ovarian-cancer/ 2026-08-24T08:00:43+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/08/Image_Lancet_24Aug26-scaled.jpg https://www.fondazionebonadonna.eu/cibisatamab-in-associazione-con-fap-4-1bbl-nel-carcinoma-del-colon-retto-metastatico-con-stabilita-dei-microsatelliti/ 2026-08-31T08:00:19+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/08/Image_Nature_31Aug26.jpg https://www.fondazionebonadonna.eu/en/cibisatamab-and-fap-4-1bbl-in-microsatellite-stable-metastatic-colorectal-cancer/ 2026-08-31T08:00:27+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/08/Image_Nature_31Aug26.jpg https://www.fondazionebonadonna.eu/relacorilant-in-aggiunta-a-nab-paclitaxel-nel-carcinoma-ovarico-resistente-al-platino/ 2026-09-07T08:00:22+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/09/Image_Lancet_07Sep26-scaled.jpg https://www.fondazionebonadonna.eu/en/relacorilant-plus-nab-paclitaxel-in-platinum-resistant-ovarian-cancer/ 2026-09-07T08:00:03+00:00 https://www.fondazionebonadonna.eu/wp-content/uploads/2026/09/Image_Lancet_07Sep26-scaled.jpg